# PeptideScanner evidence objects: Terlipressin

Every published version of the records placed with Terlipressin, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/terlipressin.json. Selected public evidence only; not medical advice.

- Objects: 63
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00089570-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT00089570

> PeptideScanner retained ClinicalTrials.gov record NCT00089570 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-10-27, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct00089570-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-10-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00089570-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct00089570-terlipressin-v1
- Content SHA-256: `edb98486a5b92c1c3ebdb1a4a0973ce4f4c9ce071525709a586645d2b9cb015b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00089570 ([`ctg-observation-nct00089570-2017-10-27-26375c70c7b7`](#source-ctg-observation-nct00089570-2017-10-27-26375c70c7b7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00089570 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-10-27, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct00089570-2017-10-27-26375c70c7b7`](#source-ctg-observation-nct00089570-2017-10-27-26375c70c7b7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00089570 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-10-27, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct00089570-2017-10-27-26375c70c7b7`](#source-ctg-observation-nct00089570-2017-10-27-26375c70c7b7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00089570-2017-10-27-26375c70c7b7`](#source-ctg-observation-nct00089570-2017-10-27-26375c70c7b7))

### Sources

<a id="source-ctg-observation-nct00089570-2017-10-27-26375c70c7b7"></a>
- **ClinicalTrials.gov record NCT00089570 · retained source version 2017-10-27:26375c70c7b7845f70741608f4b4e6405a0a48f9bad753cdadc5044440add78e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00089570) (`ctg-observation-nct00089570-2017-10-27-26375c70c7b7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00089570." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct00089570-terlipressin-v1 SHA-256: edb98486a5b92c1c3ebdb1a4a0973ce4f4c9ce071525709a586645d2b9cb015b.

---

<a id="clinicaltrials-gov-nct00115947-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT00115947

> PeptideScanner retained ClinicalTrials.gov record NCT00115947 at 2026-11-15T21:47:40.408Z. Its registry update date was 2006-03-09, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct00115947-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2006-03-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00115947-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct00115947-terlipressin-v1
- Content SHA-256: `bc13c30e08a557da79f54dbb15873bdd4be22af7825d7f37e674c137bd210a94`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00115947 ([`ctg-observation-nct00115947-2006-03-09-e4dbe4b0d8db`](#source-ctg-observation-nct00115947-2006-03-09-e4dbe4b0d8db))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00115947 at 2026-11-15T21:47:40.408Z. Its registry update date was 2006-03-09, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct00115947-2006-03-09-e4dbe4b0d8db`](#source-ctg-observation-nct00115947-2006-03-09-e4dbe4b0d8db))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00115947 at 2026-11-15T21:47:40.408Z. Its registry update date was 2006-03-09, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct00115947-2006-03-09-e4dbe4b0d8db`](#source-ctg-observation-nct00115947-2006-03-09-e4dbe4b0d8db))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00115947-2006-03-09-e4dbe4b0d8db`](#source-ctg-observation-nct00115947-2006-03-09-e4dbe4b0d8db))

### Sources

<a id="source-ctg-observation-nct00115947-2006-03-09-e4dbe4b0d8db"></a>
- **ClinicalTrials.gov record NCT00115947 · retained source version 2006-03-09:e4dbe4b0d8dbf7cb4bd58e04fda36d1505a3ea92f4677461b1403210989e0e34** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00115947) (`ctg-observation-nct00115947-2006-03-09-e4dbe4b0d8db`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00115947." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct00115947-terlipressin-v1 SHA-256: bc13c30e08a557da79f54dbb15873bdd4be22af7825d7f37e674c137bd210a94.

---

<a id="clinicaltrials-gov-nct00369694-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT00369694

> PeptideScanner retained ClinicalTrials.gov record NCT00369694 at 2026-11-15T21:47:40.408Z. Its registry update date was 2008-09-25, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct00369694-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2008-09-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00369694-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct00369694-terlipressin-v1
- Content SHA-256: `c29c02ba5b2031d3b48416faaeebd21a0c96f1b3367a2db8100ab90afec3cc52`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00369694 ([`ctg-observation-nct00369694-2008-09-25-9721251bd469`](#source-ctg-observation-nct00369694-2008-09-25-9721251bd469))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00369694 at 2026-11-15T21:47:40.408Z. Its registry update date was 2008-09-25, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct00369694-2008-09-25-9721251bd469`](#source-ctg-observation-nct00369694-2008-09-25-9721251bd469))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00369694 at 2026-11-15T21:47:40.408Z. Its registry update date was 2008-09-25, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct00369694-2008-09-25-9721251bd469`](#source-ctg-observation-nct00369694-2008-09-25-9721251bd469))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00369694-2008-09-25-9721251bd469`](#source-ctg-observation-nct00369694-2008-09-25-9721251bd469))

### Sources

<a id="source-ctg-observation-nct00369694-2008-09-25-9721251bd469"></a>
- **ClinicalTrials.gov record NCT00369694 · retained source version 2008-09-25:9721251bd469b5818ac6cd19625ec313d9d4b6c026b974c4415caed150daf73d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00369694) (`ctg-observation-nct00369694-2008-09-25-9721251bd469`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00369694." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct00369694-terlipressin-v1 SHA-256: c29c02ba5b2031d3b48416faaeebd21a0c96f1b3367a2db8100ab90afec3cc52.

---

<a id="clinicaltrials-gov-nct00370253-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT00370253

> PeptideScanner retained ClinicalTrials.gov record NCT00370253 at 2026-11-15T21:47:40.408Z. Its registry update date was 2008-04-11, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct00370253-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2008-04-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00370253-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct00370253-terlipressin-v1
- Content SHA-256: `c57ccf395a3c663c6ad13c8e84f03b878dd9990e26740597e8615a5213b1c127`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00370253 ([`ctg-observation-nct00370253-2008-04-11-730fa964b2d3`](#source-ctg-observation-nct00370253-2008-04-11-730fa964b2d3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00370253 at 2026-11-15T21:47:40.408Z. Its registry update date was 2008-04-11, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct00370253-2008-04-11-730fa964b2d3`](#source-ctg-observation-nct00370253-2008-04-11-730fa964b2d3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00370253 at 2026-11-15T21:47:40.408Z. Its registry update date was 2008-04-11, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct00370253-2008-04-11-730fa964b2d3`](#source-ctg-observation-nct00370253-2008-04-11-730fa964b2d3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00370253-2008-04-11-730fa964b2d3`](#source-ctg-observation-nct00370253-2008-04-11-730fa964b2d3))

### Sources

<a id="source-ctg-observation-nct00370253-2008-04-11-730fa964b2d3"></a>
- **ClinicalTrials.gov record NCT00370253 · retained source version 2008-04-11:730fa964b2d371933d0ea331a95ec5b609fae08d60452339849b2df65cbe3d42** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00370253) (`ctg-observation-nct00370253-2008-04-11-730fa964b2d3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00370253." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct00370253-terlipressin-v1 SHA-256: c57ccf395a3c663c6ad13c8e84f03b878dd9990e26740597e8615a5213b1c127.

---

<a id="clinicaltrials-gov-nct00628160-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT00628160

> PeptideScanner retained ClinicalTrials.gov record NCT00628160 at 2026-11-15T21:47:40.408Z. Its registry update date was 2016-02-24, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct00628160-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-02-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00628160-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct00628160-terlipressin-v1
- Content SHA-256: `d6bce7dc9601d0f6c673f25c3a39c1c7adf2c6195b39ab01d4a8e762f3f1f353`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00628160 ([`ctg-observation-nct00628160-2016-02-24-61441df0709f`](#source-ctg-observation-nct00628160-2016-02-24-61441df0709f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00628160 at 2026-11-15T21:47:40.408Z. Its registry update date was 2016-02-24, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct00628160-2016-02-24-61441df0709f`](#source-ctg-observation-nct00628160-2016-02-24-61441df0709f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00628160 at 2026-11-15T21:47:40.408Z. Its registry update date was 2016-02-24, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct00628160-2016-02-24-61441df0709f`](#source-ctg-observation-nct00628160-2016-02-24-61441df0709f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00628160-2016-02-24-61441df0709f`](#source-ctg-observation-nct00628160-2016-02-24-61441df0709f))

### Sources

<a id="source-ctg-observation-nct00628160-2016-02-24-61441df0709f"></a>
- **ClinicalTrials.gov record NCT00628160 · retained source version 2016-02-24:61441df0709f85f5515830f4e85668d2ffbb8e990652e2088072a65a2cf7acb8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00628160) (`ctg-observation-nct00628160-2016-02-24-61441df0709f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00628160." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct00628160-terlipressin-v1 SHA-256: d6bce7dc9601d0f6c673f25c3a39c1c7adf2c6195b39ab01d4a8e762f3f1f353.

---

<a id="clinicaltrials-gov-nct00986817-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT00986817

> PeptideScanner retained ClinicalTrials.gov record NCT00986817 at 2026-11-15T21:47:40.408Z. Its registry update date was 2015-06-15, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct00986817-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-06-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00986817-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct00986817-terlipressin-v1
- Content SHA-256: `25d1ea2065cb85dd792eaa307449b832063893151972901df608f99e77c5e869`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00986817 ([`ctg-observation-nct00986817-2015-06-15-5c6b09f8eb6d`](#source-ctg-observation-nct00986817-2015-06-15-5c6b09f8eb6d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00986817 at 2026-11-15T21:47:40.408Z. Its registry update date was 2015-06-15, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct00986817-2015-06-15-5c6b09f8eb6d`](#source-ctg-observation-nct00986817-2015-06-15-5c6b09f8eb6d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00986817 at 2026-11-15T21:47:40.408Z. Its registry update date was 2015-06-15, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct00986817-2015-06-15-5c6b09f8eb6d`](#source-ctg-observation-nct00986817-2015-06-15-5c6b09f8eb6d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00986817-2015-06-15-5c6b09f8eb6d`](#source-ctg-observation-nct00986817-2015-06-15-5c6b09f8eb6d))

### Sources

<a id="source-ctg-observation-nct00986817-2015-06-15-5c6b09f8eb6d"></a>
- **ClinicalTrials.gov record NCT00986817 · retained source version 2015-06-15:5c6b09f8eb6d11480ae8a13f0085f51cdd135dce9256a60a62fbdca7c2952815** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00986817) (`ctg-observation-nct00986817-2015-06-15-5c6b09f8eb6d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00986817." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct00986817-terlipressin-v1 SHA-256: 25d1ea2065cb85dd792eaa307449b832063893151972901df608f99e77c5e869.

---

<a id="clinicaltrials-gov-nct01143246-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT01143246

> PeptideScanner retained ClinicalTrials.gov record NCT01143246 at 2026-11-15T21:47:40.408Z. Its registry update date was 2022-11-29, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct01143246-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-11-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01143246-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct01143246-terlipressin-v1
- Content SHA-256: `981bf2b622484bd932898268bf1aec97f6f69f54a7f6de52973bf7ba8859809e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01143246 ([`ctg-observation-nct01143246-2022-11-29-32bdecd13bbc`](#source-ctg-observation-nct01143246-2022-11-29-32bdecd13bbc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01143246 at 2026-11-15T21:47:40.408Z. Its registry update date was 2022-11-29, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct01143246-2022-11-29-32bdecd13bbc`](#source-ctg-observation-nct01143246-2022-11-29-32bdecd13bbc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01143246 at 2026-11-15T21:47:40.408Z. Its registry update date was 2022-11-29, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct01143246-2022-11-29-32bdecd13bbc`](#source-ctg-observation-nct01143246-2022-11-29-32bdecd13bbc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01143246-2022-11-29-32bdecd13bbc`](#source-ctg-observation-nct01143246-2022-11-29-32bdecd13bbc))

### Sources

<a id="source-ctg-observation-nct01143246-2022-11-29-32bdecd13bbc"></a>
- **ClinicalTrials.gov record NCT01143246 · retained source version 2022-11-29:32bdecd13bbc6e3fd3090bfc11096d7a79834ffa1775d69e78f2a93d529e4a3f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01143246) (`ctg-observation-nct01143246-2022-11-29-32bdecd13bbc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01143246." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct01143246-terlipressin-v1 SHA-256: 981bf2b622484bd932898268bf1aec97f6f69f54a7f6de52973bf7ba8859809e.

---

<a id="clinicaltrials-gov-nct01373606-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT01373606

> PeptideScanner retained ClinicalTrials.gov record NCT01373606 at 2026-11-15T21:47:40.408Z. Its registry update date was 2012-02-14, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct01373606-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-02-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01373606-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct01373606-terlipressin-v1
- Content SHA-256: `0bb1138ec39cfa4b1820730edcb79d721c613dd50a86efb000a1451d7928c952`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01373606 ([`ctg-observation-nct01373606-2012-02-14-2c95bd5358a4`](#source-ctg-observation-nct01373606-2012-02-14-2c95bd5358a4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01373606 at 2026-11-15T21:47:40.408Z. Its registry update date was 2012-02-14, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct01373606-2012-02-14-2c95bd5358a4`](#source-ctg-observation-nct01373606-2012-02-14-2c95bd5358a4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01373606 at 2026-11-15T21:47:40.408Z. Its registry update date was 2012-02-14, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct01373606-2012-02-14-2c95bd5358a4`](#source-ctg-observation-nct01373606-2012-02-14-2c95bd5358a4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01373606-2012-02-14-2c95bd5358a4`](#source-ctg-observation-nct01373606-2012-02-14-2c95bd5358a4))

### Sources

<a id="source-ctg-observation-nct01373606-2012-02-14-2c95bd5358a4"></a>
- **ClinicalTrials.gov record NCT01373606 · retained source version 2012-02-14:2c95bd5358a44c9e83c301bda706e76cd2ee750550040d16c15160777997e608** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01373606) (`ctg-observation-nct01373606-2012-02-14-2c95bd5358a4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01373606." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct01373606-terlipressin-v1 SHA-256: 0bb1138ec39cfa4b1820730edcb79d721c613dd50a86efb000a1451d7928c952.

---

<a id="clinicaltrials-gov-nct01637454-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT01637454

> PeptideScanner retained ClinicalTrials.gov record NCT01637454 at 2026-11-15T21:47:40.408Z. Its registry update date was 2012-07-11, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct01637454-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-07-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01637454-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct01637454-terlipressin-v1
- Content SHA-256: `4df77580c875f00f6eb5ad95e026911e4f0390625d069c992cef0dddad3c9efb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01637454 ([`ctg-observation-nct01637454-2012-07-11-a75e8f9d7721`](#source-ctg-observation-nct01637454-2012-07-11-a75e8f9d7721))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01637454 at 2026-11-15T21:47:40.408Z. Its registry update date was 2012-07-11, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct01637454-2012-07-11-a75e8f9d7721`](#source-ctg-observation-nct01637454-2012-07-11-a75e8f9d7721))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01637454 at 2026-11-15T21:47:40.408Z. Its registry update date was 2012-07-11, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct01637454-2012-07-11-a75e8f9d7721`](#source-ctg-observation-nct01637454-2012-07-11-a75e8f9d7721))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01637454-2012-07-11-a75e8f9d7721`](#source-ctg-observation-nct01637454-2012-07-11-a75e8f9d7721))

### Sources

<a id="source-ctg-observation-nct01637454-2012-07-11-a75e8f9d7721"></a>
- **ClinicalTrials.gov record NCT01637454 · retained source version 2012-07-11:a75e8f9d77219b216dcb0dd2f98bba8bf1df35b75df816cc07795a71900572bf** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01637454) (`ctg-observation-nct01637454-2012-07-11-a75e8f9d7721`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01637454." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct01637454-terlipressin-v1 SHA-256: 4df77580c875f00f6eb5ad95e026911e4f0390625d069c992cef0dddad3c9efb.

---

<a id="clinicaltrials-gov-nct02059460-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT02059460

> PeptideScanner retained ClinicalTrials.gov record NCT02059460 at 2026-11-15T21:47:40.408Z. Its registry update date was 2016-12-15, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct02059460-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-12-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02059460-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct02059460-terlipressin-v1
- Content SHA-256: `850d4cb995eaa701a9b5517c1294ddd592e0825ad276018c591b36c5ae6ad72a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02059460 ([`ctg-observation-nct02059460-2016-12-15-76dc93934ec9`](#source-ctg-observation-nct02059460-2016-12-15-76dc93934ec9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02059460 at 2026-11-15T21:47:40.408Z. Its registry update date was 2016-12-15, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct02059460-2016-12-15-76dc93934ec9`](#source-ctg-observation-nct02059460-2016-12-15-76dc93934ec9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02059460 at 2026-11-15T21:47:40.408Z. Its registry update date was 2016-12-15, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct02059460-2016-12-15-76dc93934ec9`](#source-ctg-observation-nct02059460-2016-12-15-76dc93934ec9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02059460-2016-12-15-76dc93934ec9`](#source-ctg-observation-nct02059460-2016-12-15-76dc93934ec9))

### Sources

<a id="source-ctg-observation-nct02059460-2016-12-15-76dc93934ec9"></a>
- **ClinicalTrials.gov record NCT02059460 · retained source version 2016-12-15:76dc93934ec982470365f73b1ffb0a25dd5bdaad48b1bd4b551b1dc629288c77** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02059460) (`ctg-observation-nct02059460-2016-12-15-76dc93934ec9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02059460." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct02059460-terlipressin-v1 SHA-256: 850d4cb995eaa701a9b5517c1294ddd592e0825ad276018c591b36c5ae6ad72a.

---

<a id="clinicaltrials-gov-nct02588716-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT02588716

> PeptideScanner retained ClinicalTrials.gov record NCT02588716 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-12-27, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct02588716-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-12-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02588716-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct02588716-terlipressin-v1
- Content SHA-256: `aa5a4cc55efe52230a94288b41cb7484a5fd9d9ecd8b34e21e03492562884919`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02588716 ([`ctg-observation-nct02588716-2017-12-27-bba3134cf52d`](#source-ctg-observation-nct02588716-2017-12-27-bba3134cf52d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02588716 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-12-27, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct02588716-2017-12-27-bba3134cf52d`](#source-ctg-observation-nct02588716-2017-12-27-bba3134cf52d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02588716 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-12-27, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct02588716-2017-12-27-bba3134cf52d`](#source-ctg-observation-nct02588716-2017-12-27-bba3134cf52d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02588716-2017-12-27-bba3134cf52d`](#source-ctg-observation-nct02588716-2017-12-27-bba3134cf52d))

### Sources

<a id="source-ctg-observation-nct02588716-2017-12-27-bba3134cf52d"></a>
- **ClinicalTrials.gov record NCT02588716 · retained source version 2017-12-27:bba3134cf52dbc7bb00f5ac3a615a6236391f865c1698228bb3e98c977523009** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02588716) (`ctg-observation-nct02588716-2017-12-27-bba3134cf52d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02588716." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct02588716-terlipressin-v1 SHA-256: aa5a4cc55efe52230a94288b41cb7484a5fd9d9ecd8b34e21e03492562884919.

---

<a id="clinicaltrials-gov-nct02718599-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT02718599

> PeptideScanner retained ClinicalTrials.gov record NCT02718599 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-12-19, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct02718599-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-12-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02718599-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct02718599-terlipressin-v1
- Content SHA-256: `a24fc76fdefaf40f4ef5035c857d8a251ac58811a1ef447d6fa1833db8c0eb56`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02718599 ([`ctg-observation-nct02718599-2017-12-19-914a4a1e50a8`](#source-ctg-observation-nct02718599-2017-12-19-914a4a1e50a8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02718599 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-12-19, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct02718599-2017-12-19-914a4a1e50a8`](#source-ctg-observation-nct02718599-2017-12-19-914a4a1e50a8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02718599 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-12-19, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct02718599-2017-12-19-914a4a1e50a8`](#source-ctg-observation-nct02718599-2017-12-19-914a4a1e50a8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02718599-2017-12-19-914a4a1e50a8`](#source-ctg-observation-nct02718599-2017-12-19-914a4a1e50a8))

### Sources

<a id="source-ctg-observation-nct02718599-2017-12-19-914a4a1e50a8"></a>
- **ClinicalTrials.gov record NCT02718599 · retained source version 2017-12-19:914a4a1e50a8688d722e8e9d4e98530854d3a410a7b0bcf75643221f0435a1ed** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02718599) (`ctg-observation-nct02718599-2017-12-19-914a4a1e50a8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02718599." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct02718599-terlipressin-v1 SHA-256: a24fc76fdefaf40f4ef5035c857d8a251ac58811a1ef447d6fa1833db8c0eb56.

---

<a id="clinicaltrials-gov-nct02757703-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT02757703

> PeptideScanner retained ClinicalTrials.gov record NCT02757703 at 2026-11-15T21:47:40.408Z. Its registry update date was 2016-05-03, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct02757703-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-05-03
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02757703-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct02757703-terlipressin-v1
- Content SHA-256: `1318598813c6698206d0c79cc1ccc373b99e86c500e14f568d2a61d3d46a4d4a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02757703 ([`ctg-observation-nct02757703-2016-05-03-4f406e47b05c`](#source-ctg-observation-nct02757703-2016-05-03-4f406e47b05c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02757703 at 2026-11-15T21:47:40.408Z. Its registry update date was 2016-05-03, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct02757703-2016-05-03-4f406e47b05c`](#source-ctg-observation-nct02757703-2016-05-03-4f406e47b05c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02757703 at 2026-11-15T21:47:40.408Z. Its registry update date was 2016-05-03, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct02757703-2016-05-03-4f406e47b05c`](#source-ctg-observation-nct02757703-2016-05-03-4f406e47b05c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02757703-2016-05-03-4f406e47b05c`](#source-ctg-observation-nct02757703-2016-05-03-4f406e47b05c))

### Sources

<a id="source-ctg-observation-nct02757703-2016-05-03-4f406e47b05c"></a>
- **ClinicalTrials.gov record NCT02757703 · retained source version 2016-05-03:4f406e47b05c1507f864a9a1379821034f2e54cdb3926e5932455cd5739f8af2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02757703) (`ctg-observation-nct02757703-2016-05-03-4f406e47b05c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02757703." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct02757703-terlipressin-v1 SHA-256: 1318598813c6698206d0c79cc1ccc373b99e86c500e14f568d2a61d3d46a4d4a.

---

<a id="clinicaltrials-gov-nct02770716-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT02770716

> PeptideScanner retained ClinicalTrials.gov record NCT02770716 at 2026-11-15T21:47:40.408Z. Its registry update date was 2022-11-29, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct02770716-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-11-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02770716-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct02770716-terlipressin-v1
- Content SHA-256: `86461cfe447c9c1359da076156008e72f7ad0a06a711329f3b0b7165ae0b7259`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02770716 ([`ctg-observation-nct02770716-2022-11-29-0dd86b71f7a9`](#source-ctg-observation-nct02770716-2022-11-29-0dd86b71f7a9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02770716 at 2026-11-15T21:47:40.408Z. Its registry update date was 2022-11-29, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct02770716-2022-11-29-0dd86b71f7a9`](#source-ctg-observation-nct02770716-2022-11-29-0dd86b71f7a9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02770716 at 2026-11-15T21:47:40.408Z. Its registry update date was 2022-11-29, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct02770716-2022-11-29-0dd86b71f7a9`](#source-ctg-observation-nct02770716-2022-11-29-0dd86b71f7a9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02770716-2022-11-29-0dd86b71f7a9`](#source-ctg-observation-nct02770716-2022-11-29-0dd86b71f7a9))

### Sources

<a id="source-ctg-observation-nct02770716-2022-11-29-0dd86b71f7a9"></a>
- **ClinicalTrials.gov record NCT02770716 · retained source version 2022-11-29:0dd86b71f7a9687702961fb5f313cd75f8607890cd9d0e1d53d56457d31a1c2f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02770716) (`ctg-observation-nct02770716-2022-11-29-0dd86b71f7a9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02770716." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct02770716-terlipressin-v1 SHA-256: 86461cfe447c9c1359da076156008e72f7ad0a06a711329f3b0b7165ae0b7259.

---

<a id="clinicaltrials-gov-nct03107091-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT03107091

> PeptideScanner retained ClinicalTrials.gov record NCT03107091 at 2026-11-15T21:47:40.408Z. Its registry update date was 2021-07-13, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct03107091-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-07-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03107091-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct03107091-terlipressin-v1
- Content SHA-256: `1343681ff6e066ae2b7aa5d0d5daf7c345644bc8e8d31b08445a2daea617a158`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03107091 ([`ctg-observation-nct03107091-2021-07-13-06ee1b95b8fe`](#source-ctg-observation-nct03107091-2021-07-13-06ee1b95b8fe))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03107091 at 2026-11-15T21:47:40.408Z. Its registry update date was 2021-07-13, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct03107091-2021-07-13-06ee1b95b8fe`](#source-ctg-observation-nct03107091-2021-07-13-06ee1b95b8fe))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03107091 at 2026-11-15T21:47:40.408Z. Its registry update date was 2021-07-13, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct03107091-2021-07-13-06ee1b95b8fe`](#source-ctg-observation-nct03107091-2021-07-13-06ee1b95b8fe))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03107091-2021-07-13-06ee1b95b8fe`](#source-ctg-observation-nct03107091-2021-07-13-06ee1b95b8fe))

### Sources

<a id="source-ctg-observation-nct03107091-2021-07-13-06ee1b95b8fe"></a>
- **ClinicalTrials.gov record NCT03107091 · retained source version 2021-07-13:06ee1b95b8fe8e207d6eadaa9d46b1aa4150d35397fd5d2680dd7f705855568b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03107091) (`ctg-observation-nct03107091-2021-07-13-06ee1b95b8fe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03107091." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct03107091-terlipressin-v1 SHA-256: 1343681ff6e066ae2b7aa5d0d5daf7c345644bc8e8d31b08445a2daea617a158.

---

<a id="clinicaltrials-gov-nct03395574-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT03395574

> PeptideScanner retained ClinicalTrials.gov record NCT03395574 at 2026-11-15T21:47:40.408Z. Its registry update date was 2018-12-24, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct03395574-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-12-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03395574-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct03395574-terlipressin-v1
- Content SHA-256: `f3564d46e8a57b8e34ff29782331c04f4845e8ed961ad6c23ac972588a43417f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03395574 ([`ctg-observation-nct03395574-2018-12-24-9b23cd9dcb9c`](#source-ctg-observation-nct03395574-2018-12-24-9b23cd9dcb9c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03395574 at 2026-11-15T21:47:40.408Z. Its registry update date was 2018-12-24, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct03395574-2018-12-24-9b23cd9dcb9c`](#source-ctg-observation-nct03395574-2018-12-24-9b23cd9dcb9c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03395574 at 2026-11-15T21:47:40.408Z. Its registry update date was 2018-12-24, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct03395574-2018-12-24-9b23cd9dcb9c`](#source-ctg-observation-nct03395574-2018-12-24-9b23cd9dcb9c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03395574-2018-12-24-9b23cd9dcb9c`](#source-ctg-observation-nct03395574-2018-12-24-9b23cd9dcb9c))

### Sources

<a id="source-ctg-observation-nct03395574-2018-12-24-9b23cd9dcb9c"></a>
- **ClinicalTrials.gov record NCT03395574 · retained source version 2018-12-24:9b23cd9dcb9cc5a01e3dd0055cdb16e55031bbd3f7d5d7516fea980fbc517e6a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03395574) (`ctg-observation-nct03395574-2018-12-24-9b23cd9dcb9c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03395574." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct03395574-terlipressin-v1 SHA-256: f3564d46e8a57b8e34ff29782331c04f4845e8ed961ad6c23ac972588a43417f.

---

<a id="clinicaltrials-gov-nct03572088-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT03572088

> PeptideScanner retained ClinicalTrials.gov record NCT03572088 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-05-22, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct03572088-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-05-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03572088-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct03572088-terlipressin-v1
- Content SHA-256: `79d8106d90261423ae9c22c0339c3a27b61039464e980d77a3e3692fcca1c528`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03572088 ([`ctg-observation-nct03572088-2023-05-22-378f8b3c6e26`](#source-ctg-observation-nct03572088-2023-05-22-378f8b3c6e26))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03572088 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-05-22, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct03572088-2023-05-22-378f8b3c6e26`](#source-ctg-observation-nct03572088-2023-05-22-378f8b3c6e26))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03572088 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-05-22, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct03572088-2023-05-22-378f8b3c6e26`](#source-ctg-observation-nct03572088-2023-05-22-378f8b3c6e26))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03572088-2023-05-22-378f8b3c6e26`](#source-ctg-observation-nct03572088-2023-05-22-378f8b3c6e26))

### Sources

<a id="source-ctg-observation-nct03572088-2023-05-22-378f8b3c6e26"></a>
- **ClinicalTrials.gov record NCT03572088 · retained source version 2023-05-22:378f8b3c6e2616ac6ed27b8309efdaaed33a2580445bf984e7447e7638dc6c0c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03572088) (`ctg-observation-nct03572088-2023-05-22-378f8b3c6e26`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03572088." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct03572088-terlipressin-v1 SHA-256: 79d8106d90261423ae9c22c0339c3a27b61039464e980d77a3e3692fcca1c528.

---

<a id="clinicaltrials-gov-nct03584087-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT03584087

> PeptideScanner retained ClinicalTrials.gov record NCT03584087 at 2026-11-15T21:47:40.408Z. Its registry update date was 2019-12-16, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct03584087-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-12-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03584087-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct03584087-terlipressin-v1
- Content SHA-256: `9e37cf0b82d5cad9a324e76951fb1c0454c84728b2849def2fe310e34d5e6bb4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03584087 ([`ctg-observation-nct03584087-2019-12-16-4219b62b16a9`](#source-ctg-observation-nct03584087-2019-12-16-4219b62b16a9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03584087 at 2026-11-15T21:47:40.408Z. Its registry update date was 2019-12-16, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct03584087-2019-12-16-4219b62b16a9`](#source-ctg-observation-nct03584087-2019-12-16-4219b62b16a9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03584087 at 2026-11-15T21:47:40.408Z. Its registry update date was 2019-12-16, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct03584087-2019-12-16-4219b62b16a9`](#source-ctg-observation-nct03584087-2019-12-16-4219b62b16a9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03584087-2019-12-16-4219b62b16a9`](#source-ctg-observation-nct03584087-2019-12-16-4219b62b16a9))

### Sources

<a id="source-ctg-observation-nct03584087-2019-12-16-4219b62b16a9"></a>
- **ClinicalTrials.gov record NCT03584087 · retained source version 2019-12-16:4219b62b16a95afcb8b25aff04ecf3e0ca12b953855fc1caa5f5fde36cd85ed4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03584087) (`ctg-observation-nct03584087-2019-12-16-4219b62b16a9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03584087." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct03584087-terlipressin-v1 SHA-256: 9e37cf0b82d5cad9a324e76951fb1c0454c84728b2849def2fe310e34d5e6bb4.

---

<a id="clinicaltrials-gov-nct03822091-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT03822091

> PeptideScanner retained ClinicalTrials.gov record NCT03822091 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-05-09, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct03822091-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-05-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03822091-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct03822091-terlipressin-v1
- Content SHA-256: `61e663dbfb80c5f2749e7f7543bc3531fec5ed627af7978ac4054f780364c3a4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03822091 ([`ctg-observation-nct03822091-2023-05-09-f96d875a372d`](#source-ctg-observation-nct03822091-2023-05-09-f96d875a372d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03822091 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-05-09, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct03822091-2023-05-09-f96d875a372d`](#source-ctg-observation-nct03822091-2023-05-09-f96d875a372d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03822091 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-05-09, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct03822091-2023-05-09-f96d875a372d`](#source-ctg-observation-nct03822091-2023-05-09-f96d875a372d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03822091-2023-05-09-f96d875a372d`](#source-ctg-observation-nct03822091-2023-05-09-f96d875a372d))

### Sources

<a id="source-ctg-observation-nct03822091-2023-05-09-f96d875a372d"></a>
- **ClinicalTrials.gov record NCT03822091 · retained source version 2023-05-09:f96d875a372d6fee2fdf412f20778effccfea80d9a2e6aa652c46c2beb7fc4d9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03822091) (`ctg-observation-nct03822091-2023-05-09-f96d875a372d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03822091." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct03822091-terlipressin-v1 SHA-256: 61e663dbfb80c5f2749e7f7543bc3531fec5ed627af7978ac4054f780364c3a4.

---

<a id="clinicaltrials-gov-nct04358016-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT04358016

> PeptideScanner retained ClinicalTrials.gov record NCT04358016 at 2026-11-15T21:47:40.408Z. Its registry update date was 2020-04-22, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct04358016-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-04-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04358016-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct04358016-terlipressin-v1
- Content SHA-256: `052aa53026102555c7fd8c509faa40472c62183d099f0f1bb273da02ebd451bc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04358016 ([`ctg-observation-nct04358016-2020-04-22-638435dd3a6b`](#source-ctg-observation-nct04358016-2020-04-22-638435dd3a6b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04358016 at 2026-11-15T21:47:40.408Z. Its registry update date was 2020-04-22, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct04358016-2020-04-22-638435dd3a6b`](#source-ctg-observation-nct04358016-2020-04-22-638435dd3a6b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04358016 at 2026-11-15T21:47:40.408Z. Its registry update date was 2020-04-22, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct04358016-2020-04-22-638435dd3a6b`](#source-ctg-observation-nct04358016-2020-04-22-638435dd3a6b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04358016-2020-04-22-638435dd3a6b`](#source-ctg-observation-nct04358016-2020-04-22-638435dd3a6b))

### Sources

<a id="source-ctg-observation-nct04358016-2020-04-22-638435dd3a6b"></a>
- **ClinicalTrials.gov record NCT04358016 · retained source version 2020-04-22:638435dd3a6bf707fecfe0f607c905022a89c1a635e322887569724192a27ade** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04358016) (`ctg-observation-nct04358016-2020-04-22-638435dd3a6b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04358016." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct04358016-terlipressin-v1 SHA-256: 052aa53026102555c7fd8c509faa40472c62183d099f0f1bb273da02ebd451bc.

---

<a id="clinicaltrials-gov-nct04416282-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT04416282

> PeptideScanner retained ClinicalTrials.gov record NCT04416282 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-04-06, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct04416282-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-04-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04416282-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct04416282-terlipressin-v1
- Content SHA-256: `b0025b08961f434e38c592cce2173da4144dffb60bed6889512afcfac4e6509f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04416282 ([`ctg-observation-nct04416282-2023-04-06-13cb98d55058`](#source-ctg-observation-nct04416282-2023-04-06-13cb98d55058))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04416282 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-04-06, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct04416282-2023-04-06-13cb98d55058`](#source-ctg-observation-nct04416282-2023-04-06-13cb98d55058))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04416282 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-04-06, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct04416282-2023-04-06-13cb98d55058`](#source-ctg-observation-nct04416282-2023-04-06-13cb98d55058))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04416282-2023-04-06-13cb98d55058`](#source-ctg-observation-nct04416282-2023-04-06-13cb98d55058))

### Sources

<a id="source-ctg-observation-nct04416282-2023-04-06-13cb98d55058"></a>
- **ClinicalTrials.gov record NCT04416282 · retained source version 2023-04-06:13cb98d55058edba7c725c3249cd905126128efaf07591b8f36604f2b7285511** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04416282) (`ctg-observation-nct04416282-2023-04-06-13cb98d55058`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04416282." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct04416282-terlipressin-v1 SHA-256: b0025b08961f434e38c592cce2173da4144dffb60bed6889512afcfac4e6509f.

---

<a id="clinicaltrials-gov-nct04460560-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT04460560

> PeptideScanner retained ClinicalTrials.gov record NCT04460560 at 2026-11-15T21:47:40.408Z. Its registry update date was 2024-10-09, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct04460560-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-10-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04460560-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct04460560-terlipressin-v1
- Content SHA-256: `fa9aa2e80f4dc90ed8a43ba0825cf022dce981e0b2c37360f85d431b98e3fe1f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04460560 ([`ctg-observation-nct04460560-2024-10-09-5d0fb4996448`](#source-ctg-observation-nct04460560-2024-10-09-5d0fb4996448))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04460560 at 2026-11-15T21:47:40.408Z. Its registry update date was 2024-10-09, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct04460560-2024-10-09-5d0fb4996448`](#source-ctg-observation-nct04460560-2024-10-09-5d0fb4996448))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04460560 at 2026-11-15T21:47:40.408Z. Its registry update date was 2024-10-09, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct04460560-2024-10-09-5d0fb4996448`](#source-ctg-observation-nct04460560-2024-10-09-5d0fb4996448))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04460560-2024-10-09-5d0fb4996448`](#source-ctg-observation-nct04460560-2024-10-09-5d0fb4996448))

### Sources

<a id="source-ctg-observation-nct04460560-2024-10-09-5d0fb4996448"></a>
- **ClinicalTrials.gov record NCT04460560 · retained source version 2024-10-09:5d0fb4996448e189269c428051dc6df165e038ec9145f539f29c56c586c688e9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04460560) (`ctg-observation-nct04460560-2024-10-09-5d0fb4996448`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04460560." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct04460560-terlipressin-v1 SHA-256: fa9aa2e80f4dc90ed8a43ba0825cf022dce981e0b2c37360f85d431b98e3fe1f.

---

<a id="clinicaltrials-gov-nct04961528-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT04961528

> PeptideScanner retained ClinicalTrials.gov record NCT04961528 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-23, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct04961528-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04961528-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct04961528-terlipressin-v1
- Content SHA-256: `b10c9991476a86f77786109fa168c8251b3332f6c491bfb475d7184dc3c518a8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04961528 ([`ctg-observation-nct04961528-2026-04-23-737a9c3b4d22`](#source-ctg-observation-nct04961528-2026-04-23-737a9c3b4d22))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04961528 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-23, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct04961528-2026-04-23-737a9c3b4d22`](#source-ctg-observation-nct04961528-2026-04-23-737a9c3b4d22))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04961528 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-23, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct04961528-2026-04-23-737a9c3b4d22`](#source-ctg-observation-nct04961528-2026-04-23-737a9c3b4d22))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04961528-2026-04-23-737a9c3b4d22`](#source-ctg-observation-nct04961528-2026-04-23-737a9c3b4d22))

### Sources

<a id="source-ctg-observation-nct04961528-2026-04-23-737a9c3b4d22"></a>
- **ClinicalTrials.gov record NCT04961528 · retained source version 2026-04-23:737a9c3b4d22896a97cb48bc2d849c1211366d95bc467919431b4b7daea39fc7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04961528) (`ctg-observation-nct04961528-2026-04-23-737a9c3b4d22`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04961528." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct04961528-terlipressin-v1 SHA-256: b10c9991476a86f77786109fa168c8251b3332f6c491bfb475d7184dc3c518a8.

---

<a id="clinicaltrials-gov-nct05242783-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT05242783

> PeptideScanner retained ClinicalTrials.gov record NCT05242783 at 2026-11-15T21:47:40.408Z. Its registry update date was 2024-06-25, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct05242783-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-06-25
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05242783-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct05242783-terlipressin-v1
- Content SHA-256: `e884a9e7c3103ab5ddc1f3865323d0e96fef7247a2812930f12e6f0e5f939e23`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05242783 ([`ctg-observation-nct05242783-2024-06-25-95d78c5151a0`](#source-ctg-observation-nct05242783-2024-06-25-95d78c5151a0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05242783 at 2026-11-15T21:47:40.408Z. Its registry update date was 2024-06-25, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct05242783-2024-06-25-95d78c5151a0`](#source-ctg-observation-nct05242783-2024-06-25-95d78c5151a0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05242783 at 2026-11-15T21:47:40.408Z. Its registry update date was 2024-06-25, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct05242783-2024-06-25-95d78c5151a0`](#source-ctg-observation-nct05242783-2024-06-25-95d78c5151a0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05242783-2024-06-25-95d78c5151a0`](#source-ctg-observation-nct05242783-2024-06-25-95d78c5151a0))

### Sources

<a id="source-ctg-observation-nct05242783-2024-06-25-95d78c5151a0"></a>
- **ClinicalTrials.gov record NCT05242783 · retained source version 2024-06-25:95d78c5151a08815b5bc04f1847eb8f6705f52b3035b3741e83f6969a38f8415** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05242783) (`ctg-observation-nct05242783-2024-06-25-95d78c5151a0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05242783." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct05242783-terlipressin-v1 SHA-256: e884a9e7c3103ab5ddc1f3865323d0e96fef7247a2812930f12e6f0e5f939e23.

---

<a id="clinicaltrials-gov-nct06108362-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT06108362

> PeptideScanner retained ClinicalTrials.gov record NCT06108362 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct06108362-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06108362-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct06108362-terlipressin-v1
- Content SHA-256: `bfbd4875f1bc126018809fecbc65560c4fef82db4102f33383b54bfc0120bc76`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06108362 ([`ctg-observation-nct06108362-2026-10-13-1d0098eadffe`](#source-ctg-observation-nct06108362-2026-10-13-1d0098eadffe))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06108362 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct06108362-2026-10-13-1d0098eadffe`](#source-ctg-observation-nct06108362-2026-10-13-1d0098eadffe))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06108362 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct06108362-2026-10-13-1d0098eadffe`](#source-ctg-observation-nct06108362-2026-10-13-1d0098eadffe))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06108362-2026-10-13-1d0098eadffe`](#source-ctg-observation-nct06108362-2026-10-13-1d0098eadffe))

### Sources

<a id="source-ctg-observation-nct06108362-2026-10-13-1d0098eadffe"></a>
- **ClinicalTrials.gov record NCT06108362 · retained source version 2026-10-13:1d0098eadffe324161b6a37a5aefa3e24e137e58961fb1335fb8fb1dcc3876cf** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06108362) (`ctg-observation-nct06108362-2026-10-13-1d0098eadffe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06108362." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct06108362-terlipressin-v1 SHA-256: bfbd4875f1bc126018809fecbc65560c4fef82db4102f33383b54bfc0120bc76.

---

<a id="clinicaltrials-gov-nct06256432-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT06256432

> PeptideScanner retained ClinicalTrials.gov record NCT06256432 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct06256432-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06256432-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct06256432-terlipressin-v1
- Content SHA-256: `ed46587ff8eed4f5dcb197489306d7f7c3a7f09faf84b0fb608c05c37abbae7c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06256432 ([`ctg-observation-nct06256432-2026-04-13-6aa5678a4ed8`](#source-ctg-observation-nct06256432-2026-04-13-6aa5678a4ed8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06256432 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct06256432-2026-04-13-6aa5678a4ed8`](#source-ctg-observation-nct06256432-2026-04-13-6aa5678a4ed8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06256432 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct06256432-2026-04-13-6aa5678a4ed8`](#source-ctg-observation-nct06256432-2026-04-13-6aa5678a4ed8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06256432-2026-04-13-6aa5678a4ed8`](#source-ctg-observation-nct06256432-2026-04-13-6aa5678a4ed8))

### Sources

<a id="source-ctg-observation-nct06256432-2026-04-13-6aa5678a4ed8"></a>
- **ClinicalTrials.gov record NCT06256432 · retained source version 2026-04-13:6aa5678a4ed8274cbe792d1ee5d51ba8c1b9463153895290891371e86464a72a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06256432) (`ctg-observation-nct06256432-2026-04-13-6aa5678a4ed8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06256432." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct06256432-terlipressin-v1 SHA-256: ed46587ff8eed4f5dcb197489306d7f7c3a7f09faf84b0fb608c05c37abbae7c.

---

<a id="clinicaltrials-gov-nct06855758-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT06855758

> PeptideScanner retained ClinicalTrials.gov record NCT06855758 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct06855758-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06855758-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct06855758-terlipressin-v1
- Content SHA-256: `3e3ad99fa5105f6fac5c51fe29cd3d1fd7b2b6a36c1623b7285b307ded28f5a2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06855758 ([`ctg-observation-nct06855758-2026-07-13-14322bb2bb86`](#source-ctg-observation-nct06855758-2026-07-13-14322bb2bb86))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06855758 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct06855758-2026-07-13-14322bb2bb86`](#source-ctg-observation-nct06855758-2026-07-13-14322bb2bb86))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06855758 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct06855758-2026-07-13-14322bb2bb86`](#source-ctg-observation-nct06855758-2026-07-13-14322bb2bb86))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06855758-2026-07-13-14322bb2bb86`](#source-ctg-observation-nct06855758-2026-07-13-14322bb2bb86))

### Sources

<a id="source-ctg-observation-nct06855758-2026-07-13-14322bb2bb86"></a>
- **ClinicalTrials.gov record NCT06855758 · retained source version 2026-07-13:14322bb2bb866c63ed4ec588cb4806084ff927d1e32067a19f74c0cd9c634594** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06855758) (`ctg-observation-nct06855758-2026-07-13-14322bb2bb86`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06855758." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct06855758-terlipressin-v1 SHA-256: 3e3ad99fa5105f6fac5c51fe29cd3d1fd7b2b6a36c1623b7285b307ded28f5a2.

---

<a id="clinicaltrials-gov-nct07252401-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT07252401

> PeptideScanner retained ClinicalTrials.gov record NCT07252401 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct07252401-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07252401-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct07252401-terlipressin-v1
- Content SHA-256: `3b621ee59ded699d240dba1d557c1b55cfa06c46cbd0636c4b3967cde7981d55`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07252401 ([`ctg-observation-nct07252401-2026-08-27-e919bd77d693`](#source-ctg-observation-nct07252401-2026-08-27-e919bd77d693))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07252401 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct07252401-2026-08-27-e919bd77d693`](#source-ctg-observation-nct07252401-2026-08-27-e919bd77d693))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07252401 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct07252401-2026-08-27-e919bd77d693`](#source-ctg-observation-nct07252401-2026-08-27-e919bd77d693))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07252401-2026-08-27-e919bd77d693`](#source-ctg-observation-nct07252401-2026-08-27-e919bd77d693))

### Sources

<a id="source-ctg-observation-nct07252401-2026-08-27-e919bd77d693"></a>
- **ClinicalTrials.gov record NCT07252401 · retained source version 2026-08-27:e919bd77d693acedc4fb0f754cc5d077a723a96f0c424edbaf0e358de0c7dbd6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07252401) (`ctg-observation-nct07252401-2026-08-27-e919bd77d693`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07252401." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct07252401-terlipressin-v1 SHA-256: 3b621ee59ded699d240dba1d557c1b55cfa06c46cbd0636c4b3967cde7981d55.

---

<a id="clinicaltrials-gov-nct07304466-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT07304466

> PeptideScanner retained ClinicalTrials.gov record NCT07304466 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct07304466-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07304466-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct07304466-terlipressin-v1
- Content SHA-256: `b8fc6575b53e516776fed8529bf4ce0b0b96796b3cd6679385a9db517aa1e17b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07304466 ([`ctg-observation-nct07304466-2026-04-29-f83f453b92a3`](#source-ctg-observation-nct07304466-2026-04-29-f83f453b92a3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07304466 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct07304466-2026-04-29-f83f453b92a3`](#source-ctg-observation-nct07304466-2026-04-29-f83f453b92a3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07304466 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct07304466-2026-04-29-f83f453b92a3`](#source-ctg-observation-nct07304466-2026-04-29-f83f453b92a3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07304466-2026-04-29-f83f453b92a3`](#source-ctg-observation-nct07304466-2026-04-29-f83f453b92a3))

### Sources

<a id="source-ctg-observation-nct07304466-2026-04-29-f83f453b92a3"></a>
- **ClinicalTrials.gov record NCT07304466 · retained source version 2026-04-29:f83f453b92a315db9924c8a0a55914e633f04c2f99e8f74d409410a1b7a35688** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07304466) (`ctg-observation-nct07304466-2026-04-29-f83f453b92a3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07304466." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct07304466-terlipressin-v1 SHA-256: b8fc6575b53e516776fed8529bf4ce0b0b96796b3cd6679385a9db517aa1e17b.

---

<a id="clinicaltrials-gov-nct07719933-terlipressin-v1"></a>

## ClinicalTrials.gov record NCT07719933

> PeptideScanner retained ClinicalTrials.gov record NCT07719933 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was terlipressin.

- Evidence object: `story:clinicaltrials-gov-nct07719933-terlipressin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07719933-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct07719933-terlipressin-v1
- Content SHA-256: `4d1be8099853899dd4315cc23d12817c185235280230897977c2d89792206d13`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07719933 ([`ctg-observation-nct07719933-2026-07-28-88e352604eb0`](#source-ctg-observation-nct07719933-2026-07-28-88e352604eb0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07719933 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct07719933-2026-07-28-88e352604eb0`](#source-ctg-observation-nct07719933-2026-07-28-88e352604eb0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07719933 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was terlipressin. ([`ctg-observation-nct07719933-2026-07-28-88e352604eb0`](#source-ctg-observation-nct07719933-2026-07-28-88e352604eb0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07719933-2026-07-28-88e352604eb0`](#source-ctg-observation-nct07719933-2026-07-28-88e352604eb0))

### Sources

<a id="source-ctg-observation-nct07719933-2026-07-28-88e352604eb0"></a>
- **ClinicalTrials.gov record NCT07719933 · retained source version 2026-07-28:88e352604eb0c8892a0381e31bbecac4759628788c9496ec3c837877a718e822** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07719933) (`ctg-observation-nct07719933-2026-07-28-88e352604eb0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07719933." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#clinicaltrials-gov-nct07719933-terlipressin-v1 SHA-256: 4d1be8099853899dd4315cc23d12817c185235280230897977c2d89792206d13.

---

<a id="fda-drugs-nda022231-v1"></a>

## Drugs@FDA application NDA022231

> The official Drugs@FDA dataset lists original submission 1 for NDA 022231 with status AP dated 2022-09-14, and names terlipressin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda022231:v1`
- Evidence domain: Regulatory
- Date in source: 2022-09-14
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda022231/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#fda-drugs-nda022231-v1
- Content SHA-256: `33cfebebc9f3c318491473173524d48fabe38859ac612753b5bae0bb853db96d`

### Claims and source pins

#### Headline

Drugs@FDA application NDA022231 ([`fda-drugs-nda022231-2022-09-14-e8ef1dde035c`](#source-fda-drugs-nda022231-2022-09-14-e8ef1dde035c))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 022231 with status AP dated 2022-09-14, and names terlipressin acetate among the application record's active ingredients. ([`fda-drugs-nda022231-2022-09-14-e8ef1dde035c`](#source-fda-drugs-nda022231-2022-09-14-e8ef1dde035c))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 022231 with status AP dated 2022-09-14, and names terlipressin acetate among the application record's active ingredients. ([`fda-drugs-nda022231-2022-09-14-e8ef1dde035c`](#source-fda-drugs-nda022231-2022-09-14-e8ef1dde035c))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda022231-2022-09-14-e8ef1dde035c`](#source-fda-drugs-nda022231-2022-09-14-e8ef1dde035c))

### Sources

<a id="source-fda-drugs-nda022231-2022-09-14-e8ef1dde035c"></a>
- **Drugs@FDA application NDA022231 · original submission status AP · 2022-09-14 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA022231%22&limit=1) (`fda-drugs-nda022231-2022-09-14-e8ef1dde035c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA022231." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#fda-drugs-nda022231-v1 SHA-256: 33cfebebc9f3c318491473173524d48fabe38859ac612753b5bae0bb853db96d.

---

<a id="federal-register-2020-14719-v1"></a>

## Federal Register notice 2020-14719

> The Federal Register published notice 2020-14719, attributed to FDA and its parent HHS department, on 2020-07-08. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Terlipressin.

- Evidence object: `story:federal-register-2020-14719:v1`
- Evidence domain: Regulatory
- Date in source: 2020-07-08
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2020-14719/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#federal-register-2020-14719-v1
- Content SHA-256: `6d4ff9685b1f7e8d0b56b040139988b290f2fc70f569fd943bf2519a0b2a894d`

### Claims and source pins

#### Headline

Federal Register notice 2020-14719 ([`federal-register-2020-14719-90b208ccbd22`](#source-federal-register-2020-14719-90b208ccbd22))

#### Summary

The Federal Register published notice 2020-14719, attributed to FDA and its parent HHS department, on 2020-07-08. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Terlipressin. ([`federal-register-2020-14719-90b208ccbd22`](#source-federal-register-2020-14719-90b208ccbd22))

#### Paragraph 1

The Federal Register published notice 2020-14719, attributed to FDA and its parent HHS department, on 2020-07-08. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Terlipressin. ([`federal-register-2020-14719-90b208ccbd22`](#source-federal-register-2020-14719-90b208ccbd22))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2020-14719-90b208ccbd22`](#source-federal-register-2020-14719-90b208ccbd22))

### Sources

<a id="source-federal-register-2020-14719-90b208ccbd22"></a>
- **Federal Register notice 2020-14719 · published 2020-07-08 · Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2020-07-08/pdf/2020-14719.pdf) (`federal-register-2020-14719-90b208ccbd22`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2020-14719." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#federal-register-2020-14719-v1 SHA-256: 6d4ff9685b1f7e8d0b56b040139988b290f2fc70f569fd943bf2519a0b2a894d.

---

<a id="federal-register-2024-03300-v1"></a>

## Federal Register notice 2024-03300

> The Federal Register published notice 2024-03300, attributed to FDA and its parent HHS department, on 2024-02-16. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Terlipressin.

- Evidence object: `story:federal-register-2024-03300:v1`
- Evidence domain: Regulatory
- Date in source: 2024-02-16
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2024-03300/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#federal-register-2024-03300-v1
- Content SHA-256: `5bc3a11833057b8f29ad546363a134cb4e2bac0794e862e928272bf87215f321`

### Claims and source pins

#### Headline

Federal Register notice 2024-03300 ([`federal-register-2024-03300-ece4841727e2`](#source-federal-register-2024-03300-ece4841727e2))

#### Summary

The Federal Register published notice 2024-03300, attributed to FDA and its parent HHS department, on 2024-02-16. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Terlipressin. ([`federal-register-2024-03300-ece4841727e2`](#source-federal-register-2024-03300-ece4841727e2))

#### Paragraph 1

The Federal Register published notice 2024-03300, attributed to FDA and its parent HHS department, on 2024-02-16. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Terlipressin. ([`federal-register-2024-03300-ece4841727e2`](#source-federal-register-2024-03300-ece4841727e2))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2024-03300-ece4841727e2`](#source-federal-register-2024-03300-ece4841727e2))

### Sources

<a id="source-federal-register-2024-03300-ece4841727e2"></a>
- **Federal Register notice 2024-03300 · published 2024-02-16 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2024-02-16/pdf/2024-03300.pdf) (`federal-register-2024-03300-ece4841727e2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2024-03300." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#federal-register-2024-03300-v1 SHA-256: 5bc3a11833057b8f29ad546363a134cb4e2bac0794e862e928272bf87215f321.

---

<a id="pubmed-pmid-18683478-terlipressin-v1"></a>

## Role of terlipressin in the treatment of infants and neonates with catecholamine-resistant septic shock.

> PubMed lists PMID 18683478 in Best practice & research. Clinical anaesthesiology as Journal Article, Review, with publication-date metadata of 2008-06 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18683478-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18683478-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-18683478-terlipressin-v1
- Content SHA-256: `469f9f14f7dc690716b81796ad2231f3f2f27330bc2bc9d728b40b220debca9c`

### Claims and source pins

#### Headline

Role of terlipressin in the treatment of infants and neonates with catecholamine-resistant septic shock. ([`pubmed-observation-pmid-18683478-2019-11-11-6f39b10fe220`](#source-pubmed-observation-pmid-18683478-2019-11-11-6f39b10fe220))

#### Summary

PubMed lists PMID 18683478 in Best practice & research. Clinical anaesthesiology as Journal Article, Review, with publication-date metadata of 2008-06 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18683478-2019-11-11-6f39b10fe220`](#source-pubmed-observation-pmid-18683478-2019-11-11-6f39b10fe220))

#### Paragraph 1

PubMed lists PMID 18683478 in Best practice & research. Clinical anaesthesiology as Journal Article, Review, with publication-date metadata of 2008-06 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18683478-2019-11-11-6f39b10fe220`](#source-pubmed-observation-pmid-18683478-2019-11-11-6f39b10fe220))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18683478-2019-11-11-6f39b10fe220`](#source-pubmed-observation-pmid-18683478-2019-11-11-6f39b10fe220))

### Sources

<a id="source-pubmed-observation-pmid-18683478-2019-11-11-6f39b10fe220"></a>
- **Role of terlipressin in the treatment of infants and neonates with catecholamine-resistant septic shock. · retained source version 1:2019-11-11:current:6f39b10fe2207f00de55c611398e184da8af699affec349c0cabc56de55f90d4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18683478/) (`pubmed-observation-pmid-18683478-2019-11-11-6f39b10fe220`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Role of terlipressin in the treatment of infants and neonates with catecholamine-resistant septic shock." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-18683478-terlipressin-v1 SHA-256: 469f9f14f7dc690716b81796ad2231f3f2f27330bc2bc9d728b40b220debca9c.

---

<a id="pubmed-pmid-19950571-terlipressin-v1"></a>

## \[Meta-analysis of terlipressin in treatment of hepatorenal syndrome: an update\].

> PubMed lists PMID 19950571 in Zhonghua yi xue za zhi as Journal Article, Meta-Analysis, with publication-date metadata of 2009-07-28 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19950571-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19950571-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-19950571-terlipressin-v1
- Content SHA-256: `03148658933311a97bce5fcd8d7a315ac22520eada7a80126256b6f994ee8cf6`

### Claims and source pins

#### Headline

\[Meta-analysis of terlipressin in treatment of hepatorenal syndrome: an update\]. ([`pubmed-observation-pmid-19950571-2018-12-01-9acec7ee6b48`](#source-pubmed-observation-pmid-19950571-2018-12-01-9acec7ee6b48))

#### Summary

PubMed lists PMID 19950571 in Zhonghua yi xue za zhi as Journal Article, Meta-Analysis, with publication-date metadata of 2009-07-28 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19950571-2018-12-01-9acec7ee6b48`](#source-pubmed-observation-pmid-19950571-2018-12-01-9acec7ee6b48))

#### Paragraph 1

PubMed lists PMID 19950571 in Zhonghua yi xue za zhi as Journal Article, Meta-Analysis, with publication-date metadata of 2009-07-28 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19950571-2018-12-01-9acec7ee6b48`](#source-pubmed-observation-pmid-19950571-2018-12-01-9acec7ee6b48))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19950571-2018-12-01-9acec7ee6b48`](#source-pubmed-observation-pmid-19950571-2018-12-01-9acec7ee6b48))

### Sources

<a id="source-pubmed-observation-pmid-19950571-2018-12-01-9acec7ee6b48"></a>
- **\[Meta-analysis of terlipressin in treatment of hepatorenal syndrome: an update\]. · retained source version 1:2018-12-01:current:9acec7ee6b48928d3fbc234827634d235dbd848c9aefaa29d78495ec17f1290f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19950571/) (`pubmed-observation-pmid-19950571-2018-12-01-9acec7ee6b48`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Meta-analysis of terlipressin in treatment of hepatorenal syndrome: an update\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-19950571-terlipressin-v1 SHA-256: 03148658933311a97bce5fcd8d7a315ac22520eada7a80126256b6f994ee8cf6.

---

<a id="pubmed-pmid-20306131-terlipressin-v1"></a>

## Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis.

> PubMed lists PMID 20306131 in International urology and nephrology as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2010-03-20 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-20306131-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-06-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-20306131-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-20306131-terlipressin-v1
- Content SHA-256: `6d44d749c5dba4ef13d75aa835c2291ba3cf627122c9ad3daefda1d5aa5cf8ec`

### Claims and source pins

#### Headline

Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. ([`pubmed-observation-pmid-20306131-2025-06-26-07fb3f94204a`](#source-pubmed-observation-pmid-20306131-2025-06-26-07fb3f94204a))

#### Summary

PubMed lists PMID 20306131 in International urology and nephrology as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2010-03-20 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20306131-2025-06-26-07fb3f94204a`](#source-pubmed-observation-pmid-20306131-2025-06-26-07fb3f94204a))

#### Paragraph 1

PubMed lists PMID 20306131 in International urology and nephrology as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2010-03-20 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-20306131-2025-06-26-07fb3f94204a`](#source-pubmed-observation-pmid-20306131-2025-06-26-07fb3f94204a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-20306131-2025-06-26-07fb3f94204a`](#source-pubmed-observation-pmid-20306131-2025-06-26-07fb3f94204a))

### Sources

<a id="source-pubmed-observation-pmid-20306131-2025-06-26-07fb3f94204a"></a>
- **Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. · retained source version 1:2025-06-26:current:07fb3f94204ab005f9678c5feeee7106fd45e7b1a379e4492ed079479706ea19** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/20306131/) (`pubmed-observation-pmid-20306131-2025-06-26-07fb3f94204a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-20306131-terlipressin-v1 SHA-256: 6d44d749c5dba4ef13d75aa835c2291ba3cf627122c9ad3daefda1d5aa5cf8ec.

---

<a id="pubmed-pmid-22075285-terlipressin-v1"></a>

## The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study.

> PubMed lists PMID 22075285 in European journal of internal medicine as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2011-08-02 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22075285-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22075285-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-22075285-terlipressin-v1
- Content SHA-256: `1548386a2b90a77aa12f887c626cfa29bd0e0a9e1fef311b4ff35d445fd4de02`

### Claims and source pins

#### Headline

The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study. ([`pubmed-observation-pmid-22075285-2018-12-01-1a09d3989bea`](#source-pubmed-observation-pmid-22075285-2018-12-01-1a09d3989bea))

#### Summary

PubMed lists PMID 22075285 in European journal of internal medicine as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2011-08-02 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22075285-2018-12-01-1a09d3989bea`](#source-pubmed-observation-pmid-22075285-2018-12-01-1a09d3989bea))

#### Paragraph 1

PubMed lists PMID 22075285 in European journal of internal medicine as Clinical Trial, Journal Article, Multicenter Study, with publication-date metadata of 2011-08-02 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22075285-2018-12-01-1a09d3989bea`](#source-pubmed-observation-pmid-22075285-2018-12-01-1a09d3989bea))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22075285-2018-12-01-1a09d3989bea`](#source-pubmed-observation-pmid-22075285-2018-12-01-1a09d3989bea))

### Sources

<a id="source-pubmed-observation-pmid-22075285-2018-12-01-1a09d3989bea"></a>
- **The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study. · retained source version 1:2018-12-01:current:1a09d3989bead57725fc728ec7a1d60b9d00b0ea550c6acd1153d2fd71c7e5ce** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22075285/) (`pubmed-observation-pmid-22075285-2018-12-01-1a09d3989bea`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-22075285-terlipressin-v1 SHA-256: 1548386a2b90a77aa12f887c626cfa29bd0e0a9e1fef311b4ff35d445fd4de02.

---

<a id="pubmed-pmid-22322237-terlipressin-v1"></a>

## Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.

> PubMed lists PMID 22322237 in Journal of hepatology as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2012-02-06 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22322237-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-12-19
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22322237-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-22322237-terlipressin-v1
- Content SHA-256: `a6379623200028478dc5258e15c9ef359df6f82eafb5cb8adb70be3ba1342387`

### Claims and source pins

#### Headline

Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. ([`pubmed-observation-pmid-22322237-2024-12-19-ecd52517ef83`](#source-pubmed-observation-pmid-22322237-2024-12-19-ecd52517ef83))

#### Summary

PubMed lists PMID 22322237 in Journal of hepatology as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2012-02-06 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22322237-2024-12-19-ecd52517ef83`](#source-pubmed-observation-pmid-22322237-2024-12-19-ecd52517ef83))

#### Paragraph 1

PubMed lists PMID 22322237 in Journal of hepatology as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2012-02-06 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22322237-2024-12-19-ecd52517ef83`](#source-pubmed-observation-pmid-22322237-2024-12-19-ecd52517ef83))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22322237-2024-12-19-ecd52517ef83`](#source-pubmed-observation-pmid-22322237-2024-12-19-ecd52517ef83))

### Sources

<a id="source-pubmed-observation-pmid-22322237-2024-12-19-ecd52517ef83"></a>
- **Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. · retained source version 1:2024-12-19:current:ecd52517ef83fe914216e052d9d9d87d2547ae3e39549398bc310ed5dfc7f1f4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22322237/) (`pubmed-observation-pmid-22322237-2024-12-19-ecd52517ef83`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-22322237-terlipressin-v1 SHA-256: a6379623200028478dc5258e15c9ef359df6f82eafb5cb8adb70be3ba1342387.

---

<a id="pubmed-pmid-22972083-terlipressin-v1"></a>

## Terlipressin for hepatorenal syndrome.

> PubMed lists PMID 22972083 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2012-09-12 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22972083-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-06-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22972083-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-22972083-terlipressin-v1
- Content SHA-256: `7a87b0086d049fd6c7fdfeb98e321929b6dd75e7ab0fe87edf163a625d1c5d87`

### Claims and source pins

#### Headline

Terlipressin for hepatorenal syndrome. ([`pubmed-observation-pmid-22972083-2025-06-26-8f0183b154e9`](#source-pubmed-observation-pmid-22972083-2025-06-26-8f0183b154e9))

#### Summary

PubMed lists PMID 22972083 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2012-09-12 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22972083-2025-06-26-8f0183b154e9`](#source-pubmed-observation-pmid-22972083-2025-06-26-8f0183b154e9))

#### Paragraph 1

PubMed lists PMID 22972083 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2012-09-12 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22972083-2025-06-26-8f0183b154e9`](#source-pubmed-observation-pmid-22972083-2025-06-26-8f0183b154e9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22972083-2025-06-26-8f0183b154e9`](#source-pubmed-observation-pmid-22972083-2025-06-26-8f0183b154e9))

### Sources

<a id="source-pubmed-observation-pmid-22972083-2025-06-26-8f0183b154e9"></a>
- **Terlipressin for hepatorenal syndrome. · retained source version 1:2025-06-26:current:8f0183b154e99a1454109ecfa957a2e0c7a819c6cb73fef04ebe16649421016c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22972083/) (`pubmed-observation-pmid-22972083-2025-06-26-8f0183b154e9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Terlipressin for hepatorenal syndrome." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-22972083-terlipressin-v1 SHA-256: 7a87b0086d049fd6c7fdfeb98e321929b6dd75e7ab0fe87edf163a625d1c5d87.

---

<a id="pubmed-pmid-23601499-terlipressin-v1"></a>

## Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.

> PubMed lists PMID 23601499 in Liver international : official journal of the International Association for the Study of the Liver as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2013-04-21 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23601499-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23601499-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-23601499-terlipressin-v1
- Content SHA-256: `45b304f4bba471c5fed439fe1dc67d09f5e27fcc9d12b78e548bbbe851108862`

### Claims and source pins

#### Headline

Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. ([`pubmed-observation-pmid-23601499-2026-01-28-d9d8c3d4d80a`](#source-pubmed-observation-pmid-23601499-2026-01-28-d9d8c3d4d80a))

#### Summary

PubMed lists PMID 23601499 in Liver international : official journal of the International Association for the Study of the Liver as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2013-04-21 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23601499-2026-01-28-d9d8c3d4d80a`](#source-pubmed-observation-pmid-23601499-2026-01-28-d9d8c3d4d80a))

#### Paragraph 1

PubMed lists PMID 23601499 in Liver international : official journal of the International Association for the Study of the Liver as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2013-04-21 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23601499-2026-01-28-d9d8c3d4d80a`](#source-pubmed-observation-pmid-23601499-2026-01-28-d9d8c3d4d80a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23601499-2026-01-28-d9d8c3d4d80a`](#source-pubmed-observation-pmid-23601499-2026-01-28-d9d8c3d4d80a))

### Sources

<a id="source-pubmed-observation-pmid-23601499-2026-01-28-d9d8c3d4d80a"></a>
- **Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. · retained source version 1:2026-01-28:current:d9d8c3d4d80a04e7a566b0b44590cb7fb87376364f14dc924bc4a028bf52e79a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23601499/) (`pubmed-observation-pmid-23601499-2026-01-28-d9d8c3d4d80a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-23601499-terlipressin-v1 SHA-256: 45b304f4bba471c5fed439fe1dc67d09f5e27fcc9d12b78e548bbbe851108862.

---

<a id="pubmed-pmid-26334297-terlipressin-v1"></a>

## Noradrenaline or terlipressin for hepatorenal syndrome?

> PubMed lists PMID 26334297 in Medwave as Comparative Study, Journal Article, Meta-Analysis, with publication-date metadata of 2015-08-27 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26334297-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26334297-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-26334297-terlipressin-v1
- Content SHA-256: `74fcb45680c42a5f4c0f802e1e5dfa32887aae2489f63dfc485eef8bc84fbc83`

### Claims and source pins

#### Headline

Noradrenaline or terlipressin for hepatorenal syndrome? ([`pubmed-observation-pmid-26334297-2018-12-02-9fb214214140`](#source-pubmed-observation-pmid-26334297-2018-12-02-9fb214214140))

#### Summary

PubMed lists PMID 26334297 in Medwave as Comparative Study, Journal Article, Meta-Analysis, with publication-date metadata of 2015-08-27 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26334297-2018-12-02-9fb214214140`](#source-pubmed-observation-pmid-26334297-2018-12-02-9fb214214140))

#### Paragraph 1

PubMed lists PMID 26334297 in Medwave as Comparative Study, Journal Article, Meta-Analysis, with publication-date metadata of 2015-08-27 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26334297-2018-12-02-9fb214214140`](#source-pubmed-observation-pmid-26334297-2018-12-02-9fb214214140))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26334297-2018-12-02-9fb214214140`](#source-pubmed-observation-pmid-26334297-2018-12-02-9fb214214140))

### Sources

<a id="source-pubmed-observation-pmid-26334297-2018-12-02-9fb214214140"></a>
- **Noradrenaline or terlipressin for hepatorenal syndrome? · retained source version 1:2018-12-02:current:9fb214214140ae90b3eb0f6ee35655fd7966de4778eaca369210d3a7e4fb065e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26334297/) (`pubmed-observation-pmid-26334297-2018-12-02-9fb214214140`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Noradrenaline or terlipressin for hepatorenal syndrome?" Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-26334297-terlipressin-v1 SHA-256: 74fcb45680c42a5f4c0f802e1e5dfa32887aae2489f63dfc485eef8bc84fbc83.

---

<a id="pubmed-pmid-26649801-terlipressin-v1"></a>

## Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation.

> PubMed lists PMID 26649801 in European journal of gastroenterology & hepatology as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2016-03 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26649801-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26649801-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-26649801-terlipressin-v1
- Content SHA-256: `b55830dafb0385a90961946eff0b77ee30611bb64a1bf64b09695f06dc2495ce`

### Claims and source pins

#### Headline

Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. ([`pubmed-observation-pmid-26649801-2026-01-27-867f20f83403`](#source-pubmed-observation-pmid-26649801-2026-01-27-867f20f83403))

#### Summary

PubMed lists PMID 26649801 in European journal of gastroenterology & hepatology as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2016-03 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26649801-2026-01-27-867f20f83403`](#source-pubmed-observation-pmid-26649801-2026-01-27-867f20f83403))

#### Paragraph 1

PubMed lists PMID 26649801 in European journal of gastroenterology & hepatology as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2016-03 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26649801-2026-01-27-867f20f83403`](#source-pubmed-observation-pmid-26649801-2026-01-27-867f20f83403))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26649801-2026-01-27-867f20f83403`](#source-pubmed-observation-pmid-26649801-2026-01-27-867f20f83403))

### Sources

<a id="source-pubmed-observation-pmid-26649801-2026-01-27-867f20f83403"></a>
- **Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. · retained source version 1:2026-01-27:current:867f20f834034d43bc488f252ce56999d5ba018b2c06987aad2cccc8cee1a1b2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26649801/) (`pubmed-observation-pmid-26649801-2026-01-27-867f20f83403`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-26649801-terlipressin-v1 SHA-256: b55830dafb0385a90961946eff0b77ee30611bb64a1bf64b09695f06dc2495ce.

---

<a id="pubmed-pmid-27633962-terlipressin-v1"></a>

## A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock.

> PubMed lists PMID 27633962 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2016-10-20 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-27633962-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27633962-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-27633962-terlipressin-v1
- Content SHA-256: `e3931a7690a75b1fc27f57a8864c05713dbd8ee08c75f83a1e1182fbe85b540e`

### Claims and source pins

#### Headline

A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. ([`pubmed-observation-pmid-27633962-2026-01-27-0d788aef6d46`](#source-pubmed-observation-pmid-27633962-2026-01-27-0d788aef6d46))

#### Summary

PubMed lists PMID 27633962 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2016-10-20 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27633962-2026-01-27-0d788aef6d46`](#source-pubmed-observation-pmid-27633962-2026-01-27-0d788aef6d46))

#### Paragraph 1

PubMed lists PMID 27633962 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2016-10-20 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-27633962-2026-01-27-0d788aef6d46`](#source-pubmed-observation-pmid-27633962-2026-01-27-0d788aef6d46))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27633962-2026-01-27-0d788aef6d46`](#source-pubmed-observation-pmid-27633962-2026-01-27-0d788aef6d46))

### Sources

<a id="source-pubmed-observation-pmid-27633962-2026-01-27-0d788aef6d46"></a>
- **A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. · retained source version 1:2026-01-27:current:0d788aef6d46faa61a60fce459900a31b131b9ed5c9c490220e935d0fe96022d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27633962/) (`pubmed-observation-pmid-27633962-2026-01-27-0d788aef6d46`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-27633962-terlipressin-v1 SHA-256: e3931a7690a75b1fc27f57a8864c05713dbd8ee08c75f83a1e1182fbe85b540e.

---

<a id="pubmed-pmid-28689520-terlipressin-v1"></a>

## Comparison of 12-Hour with 72-Hour Terlipressin Therapy for Bleeding Esophageal Varices.

> PubMed lists PMID 28689520 in Journal of the College of Physicians and Surgeons--Pakistan : JCPSP as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2017-06 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28689520-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28689520-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-28689520-terlipressin-v1
- Content SHA-256: `6a3da8fb917d2be30ddf8399b88f3081a180e9b9dd180332d3a51e8909b133ef`

### Claims and source pins

#### Headline

Comparison of 12-Hour with 72-Hour Terlipressin Therapy for Bleeding Esophageal Varices. ([`pubmed-observation-pmid-28689520-2018-12-02-15a1f907ae4c`](#source-pubmed-observation-pmid-28689520-2018-12-02-15a1f907ae4c))

#### Summary

PubMed lists PMID 28689520 in Journal of the College of Physicians and Surgeons--Pakistan : JCPSP as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2017-06 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28689520-2018-12-02-15a1f907ae4c`](#source-pubmed-observation-pmid-28689520-2018-12-02-15a1f907ae4c))

#### Paragraph 1

PubMed lists PMID 28689520 in Journal of the College of Physicians and Surgeons--Pakistan : JCPSP as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2017-06 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28689520-2018-12-02-15a1f907ae4c`](#source-pubmed-observation-pmid-28689520-2018-12-02-15a1f907ae4c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28689520-2018-12-02-15a1f907ae4c`](#source-pubmed-observation-pmid-28689520-2018-12-02-15a1f907ae4c))

### Sources

<a id="source-pubmed-observation-pmid-28689520-2018-12-02-15a1f907ae4c"></a>
- **Comparison of 12-Hour with 72-Hour Terlipressin Therapy for Bleeding Esophageal Varices. · retained source version 1:2018-12-02:current:15a1f907ae4c497b578dcb09bd4a483bb96263f993e7e3d3589ac5282ead1231** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28689520/) (`pubmed-observation-pmid-28689520-2018-12-02-15a1f907ae4c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comparison of 12-Hour with 72-Hour Terlipressin Therapy for Bleeding Esophageal Varices." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-28689520-terlipressin-v1 SHA-256: 6a3da8fb917d2be30ddf8399b88f3081a180e9b9dd180332d3a51e8909b133ef.

---

<a id="pubmed-pmid-29943803-terlipressin-v1"></a>

## Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome.

> PubMed lists PMID 29943803 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2017-06-14 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29943803-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-06-23
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29943803-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-29943803-terlipressin-v1
- Content SHA-256: `8d03507bb9453633df4c948c441ffe97ceb2f84309f3dc23c0c94aeb24eb7904`

### Claims and source pins

#### Headline

Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. ([`pubmed-observation-pmid-29943803-2025-06-23-bad9fa5ef060`](#source-pubmed-observation-pmid-29943803-2025-06-23-bad9fa5ef060))

#### Summary

PubMed lists PMID 29943803 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2017-06-14 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29943803-2025-06-23-bad9fa5ef060`](#source-pubmed-observation-pmid-29943803-2025-06-23-bad9fa5ef060))

#### Paragraph 1

PubMed lists PMID 29943803 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2017-06-14 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29943803-2025-06-23-bad9fa5ef060`](#source-pubmed-observation-pmid-29943803-2025-06-23-bad9fa5ef060))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29943803-2025-06-23-bad9fa5ef060`](#source-pubmed-observation-pmid-29943803-2025-06-23-bad9fa5ef060))

### Sources

<a id="source-pubmed-observation-pmid-29943803-2025-06-23-bad9fa5ef060"></a>
- **Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. · retained source version 1:2025-06-23:current:bad9fa5ef06058966eda541817c7782c8eb15ccc70d2491c2ccfa44b15c5ad19** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29943803/) (`pubmed-observation-pmid-29943803-2025-06-23-bad9fa5ef060`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-29943803-terlipressin-v1 SHA-256: 8d03507bb9453633df4c948c441ffe97ceb2f84309f3dc23c0c94aeb24eb7904.

---

<a id="pubmed-pmid-30474439-terlipressin-v1"></a>

## Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence.

> PubMed lists PMID 30474439 in Current medical research and opinion as Journal Article, Review, with publication-date metadata of 2019-01-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30474439-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-03-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30474439-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-30474439-terlipressin-v1
- Content SHA-256: `1d3831b29bf63799b5025b24d6c2b03c478509edd7e22575a35ea38baec6e635`

### Claims and source pins

#### Headline

Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence. ([`pubmed-observation-pmid-30474439-2020-03-24-8833ccc3cb8b`](#source-pubmed-observation-pmid-30474439-2020-03-24-8833ccc3cb8b))

#### Summary

PubMed lists PMID 30474439 in Current medical research and opinion as Journal Article, Review, with publication-date metadata of 2019-01-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30474439-2020-03-24-8833ccc3cb8b`](#source-pubmed-observation-pmid-30474439-2020-03-24-8833ccc3cb8b))

#### Paragraph 1

PubMed lists PMID 30474439 in Current medical research and opinion as Journal Article, Review, with publication-date metadata of 2019-01-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30474439-2020-03-24-8833ccc3cb8b`](#source-pubmed-observation-pmid-30474439-2020-03-24-8833ccc3cb8b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30474439-2020-03-24-8833ccc3cb8b`](#source-pubmed-observation-pmid-30474439-2020-03-24-8833ccc3cb8b))

### Sources

<a id="source-pubmed-observation-pmid-30474439-2020-03-24-8833ccc3cb8b"></a>
- **Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence. · retained source version 1:2020-03-24:current:8833ccc3cb8b7818cfc56be77634af89703feced753285e499c0a110a554932d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30474439/) (`pubmed-observation-pmid-30474439-2020-03-24-8833ccc3cb8b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Terlipressin for the treatment of hepatorenal syndrome: an overview of current evidence." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-30474439-terlipressin-v1 SHA-256: 1d3831b29bf63799b5025b24d6c2b03c478509edd7e22575a35ea38baec6e635.

---

<a id="pubmed-pmid-31920672-terlipressin-v1"></a>

## Terlipressin Versus Norepinephrine for Septic Shock: A Systematic Review and Meta-Analysis.

> PubMed lists PMID 31920672 in Frontiers in pharmacology as Systematic Review, Journal Article, with publication-date metadata of 2019-12-23 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31920672-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-09-30
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31920672-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-31920672-terlipressin-v1
- Content SHA-256: `b9b33ddd86aae13feccbdd129a3b572a4d3ed9efb35a0596069ebe5cf4c07374`

### Claims and source pins

#### Headline

Terlipressin Versus Norepinephrine for Septic Shock: A Systematic Review and Meta-Analysis. ([`pubmed-observation-pmid-31920672-2020-09-30-f4f2986f6776`](#source-pubmed-observation-pmid-31920672-2020-09-30-f4f2986f6776))

#### Summary

PubMed lists PMID 31920672 in Frontiers in pharmacology as Systematic Review, Journal Article, with publication-date metadata of 2019-12-23 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31920672-2020-09-30-f4f2986f6776`](#source-pubmed-observation-pmid-31920672-2020-09-30-f4f2986f6776))

#### Paragraph 1

PubMed lists PMID 31920672 in Frontiers in pharmacology as Systematic Review, Journal Article, with publication-date metadata of 2019-12-23 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31920672-2020-09-30-f4f2986f6776`](#source-pubmed-observation-pmid-31920672-2020-09-30-f4f2986f6776))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31920672-2020-09-30-f4f2986f6776`](#source-pubmed-observation-pmid-31920672-2020-09-30-f4f2986f6776))

### Sources

<a id="source-pubmed-observation-pmid-31920672-2020-09-30-f4f2986f6776"></a>
- **Terlipressin Versus Norepinephrine for Septic Shock: A Systematic Review and Meta-Analysis. · retained source version 1:2020-09-30:current:f4f2986f6776b6d1b517c0c46e80b438d4257d17cdba2dc65934f720064511f4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31920672/) (`pubmed-observation-pmid-31920672-2020-09-30-f4f2986f6776`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Terlipressin Versus Norepinephrine for Septic Shock: A Systematic Review and Meta-Analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-31920672-terlipressin-v1 SHA-256: b9b33ddd86aae13feccbdd129a3b572a4d3ed9efb35a0596069ebe5cf4c07374.

---

<a id="pubmed-pmid-31941255-terlipressin-v1"></a>

## \[Research progress of terlipressin in the treatment of cirrhotic ascites-related complications\].

> PubMed lists PMID 31941255 in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology as Journal Article, Review, with publication-date metadata of 2019-12-20 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31941255-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31941255-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-31941255-terlipressin-v1
- Content SHA-256: `4d6a1bc8d40b87caec94a1bb117862c207e31a69f61629d6d5c8c22ffe2de20d`

### Claims and source pins

#### Headline

\[Research progress of terlipressin in the treatment of cirrhotic ascites-related complications\]. ([`pubmed-observation-pmid-31941255-2026-08-13-26d6c494cf38`](#source-pubmed-observation-pmid-31941255-2026-08-13-26d6c494cf38))

#### Summary

PubMed lists PMID 31941255 in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology as Journal Article, Review, with publication-date metadata of 2019-12-20 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31941255-2026-08-13-26d6c494cf38`](#source-pubmed-observation-pmid-31941255-2026-08-13-26d6c494cf38))

#### Paragraph 1

PubMed lists PMID 31941255 in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology as Journal Article, Review, with publication-date metadata of 2019-12-20 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31941255-2026-08-13-26d6c494cf38`](#source-pubmed-observation-pmid-31941255-2026-08-13-26d6c494cf38))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31941255-2026-08-13-26d6c494cf38`](#source-pubmed-observation-pmid-31941255-2026-08-13-26d6c494cf38))

### Sources

<a id="source-pubmed-observation-pmid-31941255-2026-08-13-26d6c494cf38"></a>
- **\[Research progress of terlipressin in the treatment of cirrhotic ascites-related complications\]. · retained source version 1:2026-08-13:current:26d6c494cf381bf10fce8c35350ee0175046dcba360d236609496007c27b0da0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31941255/) (`pubmed-observation-pmid-31941255-2026-08-13-26d6c494cf38`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Research progress of terlipressin in the treatment of cirrhotic ascites-related complications\]." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-31941255-terlipressin-v1 SHA-256: 4d6a1bc8d40b87caec94a1bb117862c207e31a69f61629d6d5c8c22ffe2de20d.

---

<a id="pubmed-pmid-32574418-terlipressin-v1"></a>

## Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation.

> PubMed lists PMID 32574418 in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society as Journal Article, Review, with publication-date metadata of 2020-08-09 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32574418-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-03-21
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32574418-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-32574418-terlipressin-v1
- Content SHA-256: `41194701978d84e50ae94c6ebde82740c6bd5db0ec2173cbffde9e40ec290387`

### Claims and source pins

#### Headline

Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation. ([`pubmed-observation-pmid-32574418-2024-03-21-2505a6bb5b90`](#source-pubmed-observation-pmid-32574418-2024-03-21-2505a6bb5b90))

#### Summary

PubMed lists PMID 32574418 in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society as Journal Article, Review, with publication-date metadata of 2020-08-09 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32574418-2024-03-21-2505a6bb5b90`](#source-pubmed-observation-pmid-32574418-2024-03-21-2505a6bb5b90))

#### Paragraph 1

PubMed lists PMID 32574418 in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society as Journal Article, Review, with publication-date metadata of 2020-08-09 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32574418-2024-03-21-2505a6bb5b90`](#source-pubmed-observation-pmid-32574418-2024-03-21-2505a6bb5b90))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32574418-2024-03-21-2505a6bb5b90`](#source-pubmed-observation-pmid-32574418-2024-03-21-2505a6bb5b90))

### Sources

<a id="source-pubmed-observation-pmid-32574418-2024-03-21-2505a6bb5b90"></a>
- **Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation. · retained source version 1:2024-03-21:current:2505a6bb5b903b3826dbfa76f7fa6ed5533ba8520e5fecb629c65663dc92270c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32574418/) (`pubmed-observation-pmid-32574418-2024-03-21-2505a6bb5b90`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-32574418-terlipressin-v1 SHA-256: 41194701978d84e50ae94c6ebde82740c6bd5db0ec2173cbffde9e40ec290387.

---

<a id="pubmed-pmid-32676484-terlipressin-v1"></a>

## Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence.

> PubMed lists PMID 32676484 in Canadian journal of gastroenterology & hepatology as Journal Article, Systematic Review, with publication-date metadata of 2020-06-22 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32676484-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-05-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32676484-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-32676484-terlipressin-v1
- Content SHA-256: `c349188b460b570d1ccf302fb584fc73951959dd12b9be84f5fda65e23899340`

### Claims and source pins

#### Headline

Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence. ([`pubmed-observation-pmid-32676484-2021-05-06-b85a5a020030`](#source-pubmed-observation-pmid-32676484-2021-05-06-b85a5a020030))

#### Summary

PubMed lists PMID 32676484 in Canadian journal of gastroenterology & hepatology as Journal Article, Systematic Review, with publication-date metadata of 2020-06-22 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32676484-2021-05-06-b85a5a020030`](#source-pubmed-observation-pmid-32676484-2021-05-06-b85a5a020030))

#### Paragraph 1

PubMed lists PMID 32676484 in Canadian journal of gastroenterology & hepatology as Journal Article, Systematic Review, with publication-date metadata of 2020-06-22 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32676484-2021-05-06-b85a5a020030`](#source-pubmed-observation-pmid-32676484-2021-05-06-b85a5a020030))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32676484-2021-05-06-b85a5a020030`](#source-pubmed-observation-pmid-32676484-2021-05-06-b85a5a020030))

### Sources

<a id="source-pubmed-observation-pmid-32676484-2021-05-06-b85a5a020030"></a>
- **Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence. · retained source version 1:2021-05-06:current:b85a5a020030ec51c7fd1e94ed366e72f17623d4da5b2521876208fe3db1fb6a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32676484/) (`pubmed-observation-pmid-32676484-2021-05-06-b85a5a020030`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-32676484-terlipressin-v1 SHA-256: c349188b460b570d1ccf302fb584fc73951959dd12b9be84f5fda65e23899340.

---

<a id="pubmed-pmid-33657294-terlipressin-v1"></a>

## Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.

> PubMed lists PMID 33657294 in The New England journal of medicine as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-03-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33657294-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33657294-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-33657294-terlipressin-v1
- Content SHA-256: `273add97258816aec2c4c83614d830c3dbd735597f31f6b6816ecef2da2c3ef6`

### Claims and source pins

#### Headline

Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. ([`pubmed-observation-pmid-33657294-2026-05-18-3797e8cc040e`](#source-pubmed-observation-pmid-33657294-2026-05-18-3797e8cc040e))

#### Summary

PubMed lists PMID 33657294 in The New England journal of medicine as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-03-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33657294-2026-05-18-3797e8cc040e`](#source-pubmed-observation-pmid-33657294-2026-05-18-3797e8cc040e))

#### Paragraph 1

PubMed lists PMID 33657294 in The New England journal of medicine as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-03-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33657294-2026-05-18-3797e8cc040e`](#source-pubmed-observation-pmid-33657294-2026-05-18-3797e8cc040e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33657294-2026-05-18-3797e8cc040e`](#source-pubmed-observation-pmid-33657294-2026-05-18-3797e8cc040e))

### Sources

<a id="source-pubmed-observation-pmid-33657294-2026-05-18-3797e8cc040e"></a>
- **Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. · retained source version 1:2026-05-18:current:3797e8cc040e5316cd51a9b083c641b8d7b69838707d7623fbf0d728a5b881c8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33657294/) (`pubmed-observation-pmid-33657294-2026-05-18-3797e8cc040e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-33657294-terlipressin-v1 SHA-256: 273add97258816aec2c4c83614d830c3dbd735597f31f6b6816ecef2da2c3ef6.

---

<a id="pubmed-pmid-35442343-terlipressin-v1"></a>

## RATIONAL FOR CONTINUING TERLIPRESSIN AFTER ENDOSCOPIC VARICEAL LIGATION IN ACUTE VARICEAL HAEMORRHAGE NEEDS FURTHER EVIDENCE: A PILOT STUDY.

> PubMed lists PMID 35442343 in Arquivos de gastroenterologia as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022 Jan-Mar (source-text precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35442343-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-04-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35442343-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-35442343-terlipressin-v1
- Content SHA-256: `191a07ca56146469bb7ade67e054c4a41987bf1ad59332a0626a8e700524585a`

### Claims and source pins

#### Headline

RATIONAL FOR CONTINUING TERLIPRESSIN AFTER ENDOSCOPIC VARICEAL LIGATION IN ACUTE VARICEAL HAEMORRHAGE NEEDS FURTHER EVIDENCE: A PILOT STUDY. ([`pubmed-observation-pmid-35442343-2022-04-22-6fc75dafb54e`](#source-pubmed-observation-pmid-35442343-2022-04-22-6fc75dafb54e))

#### Summary

PubMed lists PMID 35442343 in Arquivos de gastroenterologia as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022 Jan-Mar (source-text precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35442343-2022-04-22-6fc75dafb54e`](#source-pubmed-observation-pmid-35442343-2022-04-22-6fc75dafb54e))

#### Paragraph 1

PubMed lists PMID 35442343 in Arquivos de gastroenterologia as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022 Jan-Mar (source-text precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35442343-2022-04-22-6fc75dafb54e`](#source-pubmed-observation-pmid-35442343-2022-04-22-6fc75dafb54e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35442343-2022-04-22-6fc75dafb54e`](#source-pubmed-observation-pmid-35442343-2022-04-22-6fc75dafb54e))

### Sources

<a id="source-pubmed-observation-pmid-35442343-2022-04-22-6fc75dafb54e"></a>
- **RATIONAL FOR CONTINUING TERLIPRESSIN AFTER ENDOSCOPIC VARICEAL LIGATION IN ACUTE VARICEAL HAEMORRHAGE NEEDS FURTHER EVIDENCE: A PILOT STUDY. · retained source version 1:2022-04-22:current:6fc75dafb54eaa433e059d451d35e6ab7da99b541e3f6730aeba8c65bf6df65a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35442343/) (`pubmed-observation-pmid-35442343-2022-04-22-6fc75dafb54e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "RATIONAL FOR CONTINUING TERLIPRESSIN AFTER ENDOSCOPIC VARICEAL LIGATION IN ACUTE VARICEAL HAEMORRHAGE NEEDS FURTHER EVIDENCE: A PILOT STUDY." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-35442343-terlipressin-v1 SHA-256: 191a07ca56146469bb7ade67e054c4a41987bf1ad59332a0626a8e700524585a.

---

<a id="pubmed-pmid-35838488-terlipressin-v1"></a>

## Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance.

> PubMed lists PMID 35838488 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-08-03 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35838488-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35838488-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-35838488-terlipressin-v1
- Content SHA-256: `c2243b3e970c439863ce6135f14fcf84e106cf884dfa1674e72816a2e6bc5e22`

### Claims and source pins

#### Headline

Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance. ([`pubmed-observation-pmid-35838488-2025-07-28-e543243b47e7`](#source-pubmed-observation-pmid-35838488-2025-07-28-e543243b47e7))

#### Summary

PubMed lists PMID 35838488 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-08-03 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35838488-2025-07-28-e543243b47e7`](#source-pubmed-observation-pmid-35838488-2025-07-28-e543243b47e7))

#### Paragraph 1

PubMed lists PMID 35838488 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-08-03 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35838488-2025-07-28-e543243b47e7`](#source-pubmed-observation-pmid-35838488-2025-07-28-e543243b47e7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35838488-2025-07-28-e543243b47e7`](#source-pubmed-observation-pmid-35838488-2025-07-28-e543243b47e7))

### Sources

<a id="source-pubmed-observation-pmid-35838488-2025-07-28-e543243b47e7"></a>
- **Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance. · retained source version 1:2025-07-28:current:e543243b47e724d1b9d867ce37632c2b56b45ff672847fd671896faef32b0037** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35838488/) (`pubmed-observation-pmid-35838488-2025-07-28-e543243b47e7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-35838488-terlipressin-v1 SHA-256: c2243b3e970c439863ce6135f14fcf84e106cf884dfa1674e72816a2e6bc5e22.

---

<a id="pubmed-pmid-37548701-terlipressin-v1"></a>

## TERLIPRESSIN COMBINED WITH NOREPINEPHRINE IN THE TREATMENT OF SEPTIC SHOCK: A SYSTEMATIC REVIEW.

> PubMed lists PMID 37548701 in Shock (Augusta, Ga.) as Systematic Review, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-08-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37548701-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-05-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37548701-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-37548701-terlipressin-v1
- Content SHA-256: `7ff0d3e5f4c73467c3c6a98e6a6360b5c6e6720329cc7f7cd8a481b708721032`

### Claims and source pins

#### Headline

TERLIPRESSIN COMBINED WITH NOREPINEPHRINE IN THE TREATMENT OF SEPTIC SHOCK: A SYSTEMATIC REVIEW. ([`pubmed-observation-pmid-37548701-2024-05-24-d81451a0812d`](#source-pubmed-observation-pmid-37548701-2024-05-24-d81451a0812d))

#### Summary

PubMed lists PMID 37548701 in Shock (Augusta, Ga.) as Systematic Review, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-08-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37548701-2024-05-24-d81451a0812d`](#source-pubmed-observation-pmid-37548701-2024-05-24-d81451a0812d))

#### Paragraph 1

PubMed lists PMID 37548701 in Shock (Augusta, Ga.) as Systematic Review, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-08-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37548701-2024-05-24-d81451a0812d`](#source-pubmed-observation-pmid-37548701-2024-05-24-d81451a0812d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37548701-2024-05-24-d81451a0812d`](#source-pubmed-observation-pmid-37548701-2024-05-24-d81451a0812d))

### Sources

<a id="source-pubmed-observation-pmid-37548701-2024-05-24-d81451a0812d"></a>
- **TERLIPRESSIN COMBINED WITH NOREPINEPHRINE IN THE TREATMENT OF SEPTIC SHOCK: A SYSTEMATIC REVIEW. · retained source version 1:2024-05-24:current:d81451a0812db3a3cde86fbb00d369b509d93319fdb270919f5e0403f3d243f2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37548701/) (`pubmed-observation-pmid-37548701-2024-05-24-d81451a0812d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "TERLIPRESSIN COMBINED WITH NOREPINEPHRINE IN THE TREATMENT OF SEPTIC SHOCK: A SYSTEMATIC REVIEW." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-37548701-terlipressin-v1 SHA-256: 7ff0d3e5f4c73467c3c6a98e6a6360b5c6e6720329cc7f7cd8a481b708721032.

---

<a id="pubmed-pmid-38353275-terlipressin-v1"></a>

## Terlipressin for hepatorenal syndrome.

> PubMed lists PMID 38353275 in Current opinion in gastroenterology as Review, Journal Article, with publication-date metadata of 2024-03-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38353275-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-29
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38353275-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-38353275-terlipressin-v1
- Content SHA-256: `e44975f84202e75a7017f2d4689613b1f16e91d4e81563d1048c84d70382936b`

### Claims and source pins

#### Headline

Terlipressin for hepatorenal syndrome. ([`pubmed-observation-pmid-38353275-2025-07-29-b4cd887c11ad`](#source-pubmed-observation-pmid-38353275-2025-07-29-b4cd887c11ad))

#### Summary

PubMed lists PMID 38353275 in Current opinion in gastroenterology as Review, Journal Article, with publication-date metadata of 2024-03-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38353275-2025-07-29-b4cd887c11ad`](#source-pubmed-observation-pmid-38353275-2025-07-29-b4cd887c11ad))

#### Paragraph 1

PubMed lists PMID 38353275 in Current opinion in gastroenterology as Review, Journal Article, with publication-date metadata of 2024-03-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38353275-2025-07-29-b4cd887c11ad`](#source-pubmed-observation-pmid-38353275-2025-07-29-b4cd887c11ad))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38353275-2025-07-29-b4cd887c11ad`](#source-pubmed-observation-pmid-38353275-2025-07-29-b4cd887c11ad))

### Sources

<a id="source-pubmed-observation-pmid-38353275-2025-07-29-b4cd887c11ad"></a>
- **Terlipressin for hepatorenal syndrome. · retained source version 1:2025-07-29:current:b4cd887c11ad8089bea1623e1c7e260726ddbd475ad66fcd97c670243fc681a4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38353275/) (`pubmed-observation-pmid-38353275-2025-07-29-b4cd887c11ad`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Terlipressin for hepatorenal syndrome." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-38353275-terlipressin-v1 SHA-256: e44975f84202e75a7017f2d4689613b1f16e91d4e81563d1048c84d70382936b.

---

<a id="pubmed-pmid-38353565-terlipressin-v1"></a>

## From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.

> PubMed lists PMID 38353565 in Hepatology (Baltimore, Md.) as Journal Article, Review, Research Support, N.I.H., Extramural, with publication-date metadata of 2024-02-14 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38353565-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38353565-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-38353565-terlipressin-v1
- Content SHA-256: `626aa3cc1c363c6126c88dc7c41f4c463b4a263c59f2089ef51558f7d084d521`

### Claims and source pins

#### Headline

From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury. ([`pubmed-observation-pmid-38353565-2026-08-26-fde00fc3fe2d`](#source-pubmed-observation-pmid-38353565-2026-08-26-fde00fc3fe2d))

#### Summary

PubMed lists PMID 38353565 in Hepatology (Baltimore, Md.) as Journal Article, Review, Research Support, N.I.H., Extramural, with publication-date metadata of 2024-02-14 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38353565-2026-08-26-fde00fc3fe2d`](#source-pubmed-observation-pmid-38353565-2026-08-26-fde00fc3fe2d))

#### Paragraph 1

PubMed lists PMID 38353565 in Hepatology (Baltimore, Md.) as Journal Article, Review, Research Support, N.I.H., Extramural, with publication-date metadata of 2024-02-14 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38353565-2026-08-26-fde00fc3fe2d`](#source-pubmed-observation-pmid-38353565-2026-08-26-fde00fc3fe2d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38353565-2026-08-26-fde00fc3fe2d`](#source-pubmed-observation-pmid-38353565-2026-08-26-fde00fc3fe2d))

### Sources

<a id="source-pubmed-observation-pmid-38353565-2026-08-26-fde00fc3fe2d"></a>
- **From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury. · retained source version 1:2026-08-26:current:fde00fc3fe2dc90fe1c80f6879e5921d21e25bc772e4efcb20a9d61b8c2b83b6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38353565/) (`pubmed-observation-pmid-38353565-2026-08-26-fde00fc3fe2d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-38353565-terlipressin-v1 SHA-256: 626aa3cc1c363c6126c88dc7c41f4c463b4a263c59f2089ef51558f7d084d521.

---

<a id="pubmed-pmid-38526204-terlipressin-v1"></a>

## A Noninferiority Trial Comparing 2 Days vs 5 Days of Terlipressin and Ceftriaxone in Terms of 5-Day Rebleeding for Patients With Acute Gastroesophageal Variceal Hemorrhage.

> PubMed lists PMID 38526204 in The American journal of gastroenterology as Journal Article, Randomized Controlled Trial, Equivalence Trial, Comparative Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-25 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38526204-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38526204-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-38526204-terlipressin-v1
- Content SHA-256: `d7e42ae5bcb1376909aee15d7d4d3e08e5ab708dbea9cfb119e88692342c63d3`

### Claims and source pins

#### Headline

A Noninferiority Trial Comparing 2 Days vs 5 Days of Terlipressin and Ceftriaxone in Terms of 5-Day Rebleeding for Patients With Acute Gastroesophageal Variceal Hemorrhage. ([`pubmed-observation-pmid-38526204-2026-11-09-b02b4b927f48`](#source-pubmed-observation-pmid-38526204-2026-11-09-b02b4b927f48))

#### Summary

PubMed lists PMID 38526204 in The American journal of gastroenterology as Journal Article, Randomized Controlled Trial, Equivalence Trial, Comparative Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-25 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38526204-2026-11-09-b02b4b927f48`](#source-pubmed-observation-pmid-38526204-2026-11-09-b02b4b927f48))

#### Paragraph 1

PubMed lists PMID 38526204 in The American journal of gastroenterology as Journal Article, Randomized Controlled Trial, Equivalence Trial, Comparative Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-25 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38526204-2026-11-09-b02b4b927f48`](#source-pubmed-observation-pmid-38526204-2026-11-09-b02b4b927f48))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38526204-2026-11-09-b02b4b927f48`](#source-pubmed-observation-pmid-38526204-2026-11-09-b02b4b927f48))

### Sources

<a id="source-pubmed-observation-pmid-38526204-2026-11-09-b02b4b927f48"></a>
- **A Noninferiority Trial Comparing 2 Days vs 5 Days of Terlipressin and Ceftriaxone in Terms of 5-Day Rebleeding for Patients With Acute Gastroesophageal Variceal Hemorrhage. · retained source version 1:2026-11-09:current:b02b4b927f488f297ec04bdfd597025cb8f9d79174a1a06e58029b3d3fb01842** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38526204/) (`pubmed-observation-pmid-38526204-2026-11-09-b02b4b927f48`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A Noninferiority Trial Comparing 2 Days vs 5 Days of Terlipressin and Ceftriaxone in Terms of 5-Day Rebleeding for Patients With Acute Gastroesophageal Variceal Hemorrhage." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-38526204-terlipressin-v1 SHA-256: d7e42ae5bcb1376909aee15d7d4d3e08e5ab708dbea9cfb119e88692342c63d3.

---

<a id="pubmed-pmid-38560548-terlipressin-v1"></a>

## Formulary Drug Reviews: Terlipressin.

> PubMed lists PMID 38560548 in Hospital pharmacy as Journal Article, Review, with publication-date metadata of 2023-01-26 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38560548-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-12-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38560548-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-38560548-terlipressin-v1
- Content SHA-256: `9abb456199f3baf6c6e428ca53ede113664e98cdabcba9e7a79f5a8d4c6cf7ac`

### Claims and source pins

#### Headline

Formulary Drug Reviews: Terlipressin. ([`pubmed-observation-pmid-38560548-2024-12-02-9eeb11348f9f`](#source-pubmed-observation-pmid-38560548-2024-12-02-9eeb11348f9f))

#### Summary

PubMed lists PMID 38560548 in Hospital pharmacy as Journal Article, Review, with publication-date metadata of 2023-01-26 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38560548-2024-12-02-9eeb11348f9f`](#source-pubmed-observation-pmid-38560548-2024-12-02-9eeb11348f9f))

#### Paragraph 1

PubMed lists PMID 38560548 in Hospital pharmacy as Journal Article, Review, with publication-date metadata of 2023-01-26 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38560548-2024-12-02-9eeb11348f9f`](#source-pubmed-observation-pmid-38560548-2024-12-02-9eeb11348f9f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38560548-2024-12-02-9eeb11348f9f`](#source-pubmed-observation-pmid-38560548-2024-12-02-9eeb11348f9f))

### Sources

<a id="source-pubmed-observation-pmid-38560548-2024-12-02-9eeb11348f9f"></a>
- **Formulary Drug Reviews: Terlipressin. · retained source version 1:2024-12-02:current:9eeb11348f9fc803ab976a29143fdcd0fae74c1d2ed669d0eefbe9d82553946b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38560548/) (`pubmed-observation-pmid-38560548-2024-12-02-9eeb11348f9f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Formulary Drug Reviews: Terlipressin." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-38560548-terlipressin-v1 SHA-256: 9abb456199f3baf6c6e428ca53ede113664e98cdabcba9e7a79f5a8d4c6cf7ac.

---

<a id="pubmed-pmid-39295934-terlipressin-v1"></a>

## Terlipressin versus placebo or noradrenalin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.

> PubMed lists PMID 39295934 in Frontiers in pharmacology as Journal Article, Systematic Review, with publication-date metadata of 2024-09-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39295934-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-09-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39295934-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-39295934-terlipressin-v1
- Content SHA-256: `d4e1673cdc44e26c111c2218886c7c8397f80c4533ba38ed32d83c2d87623a29`

### Claims and source pins

#### Headline

Terlipressin versus placebo or noradrenalin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. ([`pubmed-observation-pmid-39295934-2024-09-20-9d15edddc5f7`](#source-pubmed-observation-pmid-39295934-2024-09-20-9d15edddc5f7))

#### Summary

PubMed lists PMID 39295934 in Frontiers in pharmacology as Journal Article, Systematic Review, with publication-date metadata of 2024-09-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39295934-2024-09-20-9d15edddc5f7`](#source-pubmed-observation-pmid-39295934-2024-09-20-9d15edddc5f7))

#### Paragraph 1

PubMed lists PMID 39295934 in Frontiers in pharmacology as Journal Article, Systematic Review, with publication-date metadata of 2024-09-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39295934-2024-09-20-9d15edddc5f7`](#source-pubmed-observation-pmid-39295934-2024-09-20-9d15edddc5f7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39295934-2024-09-20-9d15edddc5f7`](#source-pubmed-observation-pmid-39295934-2024-09-20-9d15edddc5f7))

### Sources

<a id="source-pubmed-observation-pmid-39295934-2024-09-20-9d15edddc5f7"></a>
- **Terlipressin versus placebo or noradrenalin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. · retained source version 1:2024-09-20:current:9d15edddc5f758faf4b045e92b4e7b711d00340531b5b960f8a8d9e94ac37cde** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39295934/) (`pubmed-observation-pmid-39295934-2024-09-20-9d15edddc5f7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Terlipressin versus placebo or noradrenalin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-39295934-terlipressin-v1 SHA-256: d4e1673cdc44e26c111c2218886c7c8397f80c4533ba38ed32d83c2d87623a29.

---

<a id="pubmed-pmid-39618221-terlipressin-v1"></a>

## The Application of Terlipressin in the Management of Ascites in Liver Cirrhosis: Current Status and Prospects.

> PubMed lists PMID 39618221 in British journal of hospital medicine (London, England : 2005) as Journal Article, Review, with publication-date metadata of 2024-11-25 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39618221-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-12-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39618221-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-39618221-terlipressin-v1
- Content SHA-256: `8fc167ecc8a61aac11a00d17841f3c59bf8f891e1f5e6168826fdf1cbd690836`

### Claims and source pins

#### Headline

The Application of Terlipressin in the Management of Ascites in Liver Cirrhosis: Current Status and Prospects. ([`pubmed-observation-pmid-39618221-2024-12-05-738fbf3bff92`](#source-pubmed-observation-pmid-39618221-2024-12-05-738fbf3bff92))

#### Summary

PubMed lists PMID 39618221 in British journal of hospital medicine (London, England : 2005) as Journal Article, Review, with publication-date metadata of 2024-11-25 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39618221-2024-12-05-738fbf3bff92`](#source-pubmed-observation-pmid-39618221-2024-12-05-738fbf3bff92))

#### Paragraph 1

PubMed lists PMID 39618221 in British journal of hospital medicine (London, England : 2005) as Journal Article, Review, with publication-date metadata of 2024-11-25 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39618221-2024-12-05-738fbf3bff92`](#source-pubmed-observation-pmid-39618221-2024-12-05-738fbf3bff92))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39618221-2024-12-05-738fbf3bff92`](#source-pubmed-observation-pmid-39618221-2024-12-05-738fbf3bff92))

### Sources

<a id="source-pubmed-observation-pmid-39618221-2024-12-05-738fbf3bff92"></a>
- **The Application of Terlipressin in the Management of Ascites in Liver Cirrhosis: Current Status and Prospects. · retained source version 1:2024-12-05:current:738fbf3bff925eec9b7d14b765546f824880030a3d9ba0426a49e2568b503c6c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39618221/) (`pubmed-observation-pmid-39618221-2024-12-05-738fbf3bff92`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The Application of Terlipressin in the Management of Ascites in Liver Cirrhosis: Current Status and Prospects." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-39618221-terlipressin-v1 SHA-256: 8fc167ecc8a61aac11a00d17841f3c59bf8f891e1f5e6168826fdf1cbd690836.

---

<a id="pubmed-pmid-41200852-terlipressin-v1"></a>

## Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure.

> PubMed lists PMID 41200852 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-12 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41200852-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-11
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41200852-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-41200852-terlipressin-v1
- Content SHA-256: `4de807139495ce88d50f500fc63997227ded4c63d20cd92f0a5ae19c5c40eb0e`

### Claims and source pins

#### Headline

Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure. ([`pubmed-observation-pmid-41200852-2026-08-11-01b871ef5dc9`](#source-pubmed-observation-pmid-41200852-2026-08-11-01b871ef5dc9))

#### Summary

PubMed lists PMID 41200852 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-12 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41200852-2026-08-11-01b871ef5dc9`](#source-pubmed-observation-pmid-41200852-2026-08-11-01b871ef5dc9))

#### Paragraph 1

PubMed lists PMID 41200852 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-12 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41200852-2026-08-11-01b871ef5dc9`](#source-pubmed-observation-pmid-41200852-2026-08-11-01b871ef5dc9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41200852-2026-08-11-01b871ef5dc9`](#source-pubmed-observation-pmid-41200852-2026-08-11-01b871ef5dc9))

### Sources

<a id="source-pubmed-observation-pmid-41200852-2026-08-11-01b871ef5dc9"></a>
- **Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure. · retained source version 1:2026-08-11:current:01b871ef5dc97d6bda2e5f333451a653783f5b5c1e76798a27c37eff874b5994** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41200852/) (`pubmed-observation-pmid-41200852-2026-08-11-01b871ef5dc9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-41200852-terlipressin-v1 SHA-256: 4de807139495ce88d50f500fc63997227ded4c63d20cd92f0a5ae19c5c40eb0e.

---

<a id="pubmed-pmid-41204083-terlipressin-v1"></a>

## The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review.

> PubMed lists PMID 41204083 in BMC anesthesiology as Journal Article, Case Reports, Review, with publication-date metadata of 2025-11-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41204083-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-04
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41204083-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-41204083-terlipressin-v1
- Content SHA-256: `0ceecf742442548c87c5ee0d8e59bd3e012d82c6b6200dbe068e4999b06c74c8`

### Claims and source pins

#### Headline

The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review. ([`pubmed-observation-pmid-41204083-2026-11-04-bd8c6f911737`](#source-pubmed-observation-pmid-41204083-2026-11-04-bd8c6f911737))

#### Summary

PubMed lists PMID 41204083 in BMC anesthesiology as Journal Article, Case Reports, Review, with publication-date metadata of 2025-11-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41204083-2026-11-04-bd8c6f911737`](#source-pubmed-observation-pmid-41204083-2026-11-04-bd8c6f911737))

#### Paragraph 1

PubMed lists PMID 41204083 in BMC anesthesiology as Journal Article, Case Reports, Review, with publication-date metadata of 2025-11-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41204083-2026-11-04-bd8c6f911737`](#source-pubmed-observation-pmid-41204083-2026-11-04-bd8c6f911737))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41204083-2026-11-04-bd8c6f911737`](#source-pubmed-observation-pmid-41204083-2026-11-04-bd8c6f911737))

### Sources

<a id="source-pubmed-observation-pmid-41204083-2026-11-04-bd8c6f911737"></a>
- **The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review. · retained source version 1:2026-11-04:current:bd8c6f911737d7c40d7174311df1225c510852d8dce060411db3111d8f631376** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41204083/) (`pubmed-observation-pmid-41204083-2026-11-04-bd8c6f911737`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-41204083-terlipressin-v1 SHA-256: 0ceecf742442548c87c5ee0d8e59bd3e012d82c6b6200dbe068e4999b06c74c8.

---

<a id="pubmed-pmid-41711944-terlipressin-v1"></a>

## Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI).

> PubMed lists PMID 41711944 in Pediatric nephrology (Berlin, Germany) as Journal Article, Review, with publication-date metadata of 2026-02-19 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41711944-terlipressin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41711944-terlipressin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-41711944-terlipressin-v1
- Content SHA-256: `42edb4d9e13d08b70515ee740e203a21a6345f52d18136ac0492d2562568e287`

### Claims and source pins

#### Headline

Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI). ([`pubmed-observation-pmid-41711944-2026-08-20-52510674bdeb`](#source-pubmed-observation-pmid-41711944-2026-08-20-52510674bdeb))

#### Summary

PubMed lists PMID 41711944 in Pediatric nephrology (Berlin, Germany) as Journal Article, Review, with publication-date metadata of 2026-02-19 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41711944-2026-08-20-52510674bdeb`](#source-pubmed-observation-pmid-41711944-2026-08-20-52510674bdeb))

#### Paragraph 1

PubMed lists PMID 41711944 in Pediatric nephrology (Berlin, Germany) as Journal Article, Review, with publication-date metadata of 2026-02-19 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41711944-2026-08-20-52510674bdeb`](#source-pubmed-observation-pmid-41711944-2026-08-20-52510674bdeb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41711944-2026-08-20-52510674bdeb`](#source-pubmed-observation-pmid-41711944-2026-08-20-52510674bdeb))

### Sources

<a id="source-pubmed-observation-pmid-41711944-2026-08-20-52510674bdeb"></a>
- **Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI). · retained source version 1:2026-08-20:current:52510674bdeb961d3902e09f6e8bda2dc8870668d737d4f83ab71a55dad1df6a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41711944/) (`pubmed-observation-pmid-41711944-2026-08-20-52510674bdeb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI)." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/terlipressin.json#pubmed-pmid-41711944-terlipressin-v1 SHA-256: 42edb4d9e13d08b70515ee740e203a21a6345f52d18136ac0492d2562568e287.

